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Bone is a living tissue. Throughout life the skeleton constantly maintains its 
structural integrity by replacing old or damaged bone with newly laid down bone by 
a process called remodelling. This process of bone remodelling is accomplished by a 
tight collaboration between bone resorbing osteoclasts and bone forming osteoblasts, 
working together as a basic multicellular unit (BMU) (Figure 1). Bone remodelling 
commences by attraction of osteoclast precursors to bone sites, where they further 
differentiate into mature multinucleated osteoclasts, which start to resorb bone, leaving 
behind a resorption cavity. Osteoblasts are subsequently attracted to this resorption 
pit by signals derived from the osteoclasts and stimulatory factors embedded in the 
bone matrix, released by resorption (1). Over a period of 3 to 4 months the resorption 
cavity is refilled with new layers of bone matrix, layed down by the osteoblasts, which 
subsequently mineralizes. In healthy adults, the amount of bone formed equals that 
initially resorbed. The activity of osteoclasts and osteoblasts are tightly regulated, 
by each other, but also by a third type of bone cell, the osteocyte (2,3). Osteocytes 
are terminally differentiated osteoblasts embedded in the bone. During the process 
of bone formation, about 10-20% of the osteoblasts are buried in the bone matrix by 
the advancing osteoblasts. These cells differentiate into osteocytes, developing long 
dendritic processes through which they keep contact with the osteoblasts on the bone 
surface. This way osteocytes can be found regularly scattered throughout the bone, 
making up for more the 90% of all bone cells, and forming a dense network with their 
dendritic pseudopods, through which they can communicate with each other and 
cells on the bone surface (4). 
For many years osteocytes were thought to be involved in the regulation of bone 
remodelling, but due to their embedment in bone, these cells were difficult to study, 
and their exact function remained an enigma. However, recent studies illustrated 
that osteocytes are indeed the main orchestrators of bone remodelling. Osteocytes 
produce RANKL, a major stimulatory signal for osteoclast differentiation and 
activity, by which they can regulate bone resorption (6,7). Similarly osteocytes can 
control the rate of bone formation by synthesizing sclerostin, a key inhibitory signal 
for osteoblast activity and lifespan (8).
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Disturbances in the balance between bone resorption and bone formation form the 
pathophysiological basis of many bone diseases. The most prevalent bone disease is 
osteoporosis, in which an increased bone resorption is not sufficiently compensated by 
bone formation, leading to gradual bone loss and deterioration of its microstructure 
leading to increased bone fragility (9). Conversely, there are several, less prevalent, 
bone disorders in which there is an imbalance in favour of bone formation, leading to 
increased accumulation of bone and thick bones. These sclerosing bone disorders can 
be caused either by impaired production or activity of osteoclasts (osteopetroses), or 
by increased production of osteoblasts (hyperostoses or osteoscleroses) (10). Sclerostin 
was discovered a decade ago by studies of two such bone sclerosing dysplasias namely, 
sclerosteosis and van Buchem disease (11-14). Both these disorders are the result of 
impaired sclerostin synthesis, leading to an imbalance of bone remodelling in favour 
of bone formation. 
The aim of this Thesis is the investigation of the role of sclerostin in bone metabolism 
in humans. In Chapter 1 we review current knowledge of sclerostin, and the sclerostin-
deficient disorders sclerosteosis and van Buchem disease. In Chapter 2, we describe 
the characteristics and performance of the assay we used to measure sclerostin levels 
Figure 1. A schematic overview of the bone remodelling cycle. Lining cells and osteocytes release 
local factors that attract cells from blood and marrow into the remodeling compartment in which 
osteoclastogenesis occurs. Osteoclasts resorb matrix, then successive teams of osteoblasts deposit 
new lamellar bone. Osteoblasts that are trapped in the matrix become osteocytes; others die or 
form new, flattened osteoblast lining cells. Reproduced with permission from the New England 
Journal of Medicine (5), Copyright Massachusetts Medical Society
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in blood. In Chapters 3 and 4 we report studies of patients and disease carriers of 
sclerosteosis and van Buchem disease, respectively.  In Chapter 5 we present the 
results of treatment of van Buchem disease with glucocorticoids. In the subsequent 
Chapters we report studies of the regulation of sclerostin synthesis by systemic factors, 
such as glucocorticoids (Chapter 6) and PTH (Chapter 7) and the role of sclerostin 
in type 2 diabetes mellitus (Chapter 8), Paget’s disease of bone and prostate cancer 
metastatic to the skeleton (Chapter 9).
References 
 1.  Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA. Local communication on and within 
bone controls bone remodeling. Bone 2009;44:1026-1033.
 2.  Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008;473:201-209.
 3.  Noble BS. The osteocyte lineage. Arch Biochem Biophys 2008;473:106-111.
 4.  Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011;26:229-238.
  5.   Seeman E, and Delmas PD. Bone Quality - The Material and 
        Structural Basis of Bone Strength and Fragility. N Engl J Med   
        2006;354:2250-2261. 
 6.  Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama 
T, Wutz A, Wagner EF, Penninger JM, Takayanagi H. Evidence for osteocyte regulation of bone 
homeostasis through RANKL expression. Nat Med 2011;17:1231-1234.
 7.  Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O’Brien CA. Matrix-embedded cells 
control osteoclast formation. Nat Med 2011;17:1235-1241.
 8.  van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals, de Wilt E, Karperien M, Hamersma 
H, Papapoulos SE, ten Dijke P, Lowik CW. Sclerostin is an osteocyte-expressed negative regulator 
of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805-814.
    9.    Manolagas SC. Birth and death of bone cells: basic regulatory    
 mechanisms and implications for the pathogenesis and treatment of 
    osteoporosis. Endocr Rev 2000;21:115-37 .
   10.    de Vernejoul MC. Sclerosing bone disorders. Best Pract Res Clin Rheumatol 2008;22:71-83.
 11.  Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, 
Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P 
preface
13
& Mulligan J. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel 
cystine knot-containing protein. Am J Hum Genet 2001;68:577-589.
 12.  Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den 
EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis 
C, Lindpaintner K, Vickery B, Foernzler D & Van HW. Increased bone density in sclerosteosis is 
due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10: 537-543.
   13.   Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas 
D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H & Brunkow ME. A 52-kb deletion in 
the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the 
Dutch population. Am J Med Genet 2002;110:144-152.

Chapter 1
The role of sclerostin in the pathophysiology 
of sclerosing bone dysplasias
A.H. van Lierop
N.A.T. Hamdy
 R.L. van Bezooijen
 C.W.Löwik
 S.E. Papapoulos
Clinic Rev Bone Miner Metab. 2012;10:108-116
16
Introduction
Osteocytes, the most abundant cells in bone, are terminally differentiated osteoblasts 
burried in the bone matrix which are key regulators of bone remodelling and have 
also important functions in the regulation of mineral metabolism [1]. Osteocytes act 
on both osteoclasts and osteoblasts. They synthesize receptor activator of nuclear 
factor kappa-B ligand (RANKL) [2,3], which is essential for osteoclast proliferation, 
differentiation and survival, and are the main source of sclerostin which inhibits 
bone formation by the osteoblasts [4]. Whereas animal models were pivotal for the 
discovery of RANKL and its role in bone resorption [5], it is human studies of two 
rare bone sclerosing dysplasias, sclerosteosis [6,7] and van Buchem disease (VBD) 
[8,9] that have led to the discovery of sclerostin. Both these disorders are caused 
by deficient synthesis of sclerostin, resulting in unrestrained bone formation and 
progressive generalized hyperostosis.  
We review here current knowledge of the mechanism of action and the regulation 
of synthesis of sclerostin, and of its role in the pathophysiology of sclerosteosis and 
VBD. 
Sclerostin synthesis
Osteocytes synthesize sclerostin in the late stages of their differentiation, after 
maturation and after the start of mineralization of the surrounding bone matrix [10] 
(figure 1). Newly synthesized sclerostin is then transported to the bone surface through 
the dendritic network of osteocytes, where it inhibits the activity of osteoblasts and 
stimulates their apoptosis [4,11]. Recent evidence, suggests that sclerostin has also 
an autocrine function [12]. Furthermore, sclerostin  upregulates RANKL synthesis 
thereby stimulating osteoclastogenesis [13]. Although osteocytes are the predominant 
source of sclerostin, other cell types embedded in mineralized matrices, such as 
chondrocytes [11] and cementocytes [14],  have also been found to produce sclerostin 
Sclerostin is the product of the SOST gene, a relatively small gene comprising two 
exons, situated  on chromosome 17q12-q21. The SOST gene is highly conserved 
among vertebrates, with the amino acid sequence of murine sclerostin being 88% 
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homologous with the human protein [6]. Moreover, SOST knock-out mice develop a 
high-bone-mass phenotype similar to that of sclerosteosis patients [15], whereas mice 
overexpressing SOST become osteopenic [11].  In addition to bone, cartilage and 
cementum, transcripts of SOST have also been found in kidney, liver, and heart [6,7], 
but no sclerostin expression could be detected in any of these tissues in human [16]. 
In keeping with this finding, patients with sclerostin deficiency have normal renal and 
liver function and no specific cardiac abnormalities [17-19]. 
Sclerostin antagonizes the canonical Wnt signaling pathway
Sclerostin decreases bone formation by antagonizing the canonical Wnt signaling 
pathway in osteoblasts thereby inhibiting the proliferation, differentiation and 
survival of these cells [20-22]. Secreted Wnt ligands bind to a co-receptor complex of 
the low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) receptor and a 
trans membrane frizzled receptor. Upon binding, intracellular β-catenin is prevented 
from degradation and accumulates in the cytoplasm. β-catenin is translocated to 
Figure 1. Role of sclerostin in bone remodeling. Sclerostin is synthesized by matured osteocytes 
at the initiation of mineralization of new bone. Sclerostin act on the osteoblasts on the bone 
surface, by inhibiting their bone forming activity and life-span. Sclerostin can also indirectly 
stimulate bone resorption by up regulating RANKL synthesis by osteocytes in an autocrine 
manner. 
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the nucleus and triggers the transcription of target genes through the interaction 
with TCF/LEF-1 transcription factors [23] (figure 2A). Sclerostin binds to the first 
propeller domain of the LRP5/6 receptor [21], thereby disabling the formation of 
the co-receptor complex between LRP5/6 and the frizzled receptor, and inhibiting 
the Wnt pathway high up in the signalling cascade (figure2B). Whereas, the exact 
mechanism by which sclerostin interacts with the LRP5/6 receptor remains to be 
established, it is thought that it requires an, as yet to be identified, co-factor to 
inhibit the Wnt pathway similar to another Wnt antagonist, DKK1, which needs 
Kremen to inhibit the pathway [24]. LRP4 was recently proposed to be a mediator 
of sclerostin’s inhibitory function on bone formation and mutations in LRP4 were 
identified in patients with a phenotype closely resembling that of sclerosteosis [25] 
Figure 2.  Mechanism of inhibition of canonical Wnt signalling by sclerostin
Sclerostin is an antagonist of the canonical Wnt signalling pathway. A: the Wnt signalling pathway 
is initiated by the binding of Wnt ligands to a co-receptor complex of LRP5/6 and the frizzled 
receptor. Wnt signaling is essential for osteoblast proliferation, differentiation and survival, and is 
thus the main stimulatory pathway of bone formation. B: sclerostin antagonizes the Wnt signalling 
pathway by inhibiting the formation of the LRP5/6-frizzled co-receptor complex, through binding 
to the LRP5/6 receptor, possibly facilitated by a (unknown) co-factor.   
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Sclerosing bone disorders associated with sclerostin deficiency
The significance of the role of sclerostin as a negative regulator of bone formation is 
highlighted by the characteristic phenotypes of patients with sclerosteosis and VBD, 
two bone sclerosing dysplasias belonging to the group of craniotubular hyperostosis 
[26] caused by genetically determined sclerostin deficiency, and characterized by very 
high bone mass. 
Sclerosteosis (OMIM 269500) was described in 1958 by Trushwell as ‘osteopetrosis 
with syndactyly’ [27] and less than 100 cases have since been reported in the 
literature. Sclerosteosis is an autosomal recessive disorder caused by mutations in 
the SOST gene. Six different mutations have been reported so far resulting in either 
impaired synthesis of sclerostin [6,7,28], or synthesis of a non-functioning protein 
[29]. Although isolated cases of sclerosteosis have been reported in different parts 
of the world, the majority of patients are members of the Afrikaner community of 
South Africa, descendants of Dutch immigrants who settled in this country in the 
17th century. Although the homozygous state is rare, the carrier rate of the SOST 
mutation in the Afrikaner  population has been estimated to be as high as 1 in 140 
individuals [30]. Van Buchem disease (OMIM 239100), first described by professor van 
Buchem and his colleagues in 1955 as ‘hyperostosis corticalis generalisata familiaris’ 
[31], is a sclerosing bone dysplasia also inherited as an autosomal recessive trait. In 
this disorder the SOST gene is intact, but patients lack a regulatory element essential 
for the postnatal transcription of SOST in bone [32] due to a 52 kb deletion 35 kb 
downstream of the SOST gene [8,9]. About 30 cases of VBD have been so far described, 
the vast majority being inhabitants of  a small village in north Holland. This village 
used to be an island off the coast until extensive land reclamation connected it to 
the mainland in the 1940s. Two siblings with VBD have been reported by German 
investigators, but the origin of the patients was not mentioned in the paper [33] so 
possible Dutch ancestry cannot be excluded. 
The clinical features of sclerosteosis have been extensively described [17,34,35]. 
The most prominent of these features are due to overgrowth of the bones of the 
skull. Mandibular overgrowth, and elongation of the forehead [17,34] result in facial 
distortion which becomes evident before the onset of puberty [17,34] (figure 3). 
Sclerostin and sclerostin deficiency disorders
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Excessive bone formation in skull bones eventually give rise to serious complications, 
the most common being cranial nerve entrapment syndromes due to obliteration of 
neural foramina (figure 4), with the facial nerve being the most frequently affected. 
This is often the first complication of the disease, occurring generally before the fifth 
year of life, although facial palsy may also be observed at birth [34,35]. Unilateral or 
bilateral facial palsy eventually develops in almost all patients [17,34,35,37]. Hearing 
loss is the second most frequently encountered complication of sclerosteosis. It usually 
starts in early childhood as pure conductive deafness, due to fixation of the ossicles in 
the inner ear, with a sensorineural component often developing later in life as a result 
of narrowing of the round and oval windows, or of impingement of the acoustic nerve 
in the internal acoustic canal [17,34,35,37]. Although rare, symptoms associated with 
entrapment of other cranial nerves, such as loss of vision or sense of smell have also 
Figure 3. Chronological portraits of a patient with sclerosteosis from the age of 3 years 
onward. She was born with syndactyly at both hands and developed facial  palsy, deafness, 
facial distortion, and maxillary overgrowth during childhood. By the age of 30, she had 
developed proptosis and elevated intracranial pressure due to overgrowth of the calvaria. 
Craniectomy was performed, but she died nevertheless because of elevated intracranial 
pressure at the age of 54 years (description of this case was previously published by Epstein 
et al.[36]). Reproduced with permission of Calcified Tissue International.
Chapter 1
21
been reported [34,37]. However, the most severe, and life-threatening complication of 
sclerosteosis is increased intracranial pressure [17,35]. This develops in the majority of 
patients as a result of a decreased intracranial volume due to considerable thickening 
of the calvaria and skull base. In the past this has been a common cause of sudden 
death of patients with sclerosteosis [17] due to medullary compression. Although the 
course of sclerosteosis is evidently progressive during childhood and adolescence, the 
disease appears to stabilize after the third decade [34,35,38]. 
Figure 4. Skull of a sclerosteosis patient (lower panel) compared to that of a normal subject 
(upper panel). Severely narrowed internal acoustic meatus in the patient (black arrow) 
compared to that of the normal subject (white arrow). The greatly thickened calvarium of the 
patient can also be noted (dotted line).
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The phenotype of patients with VBD is highly similar to that of sclerosteosis except 
for two distinctive features of sclerosteosis, which have so far never been reported in 
patients with VBD, namely syndactyly and tall stature [39] (Table 1). There can be, 
however, a great variation in the severity of disease manifestations among patients 
with VBD [39]; van Lierop et al in preparation]. While the phenotype of severe cases 
with VBD is highly similar to that of patients with sclerosteosis, other patients with 
VBD have mild abnormalities and only few lifelong complications. Facial distortion 
is a consistent feature of VBD [19] but less prominent than in sclerosteosis [39]. In 
the majority of patients facial palsy also develops in the first years of life [18,40], and 
had been also present at birth in some patients. The presence and severity of hearing 
loss varies greatly among VBD patients, being profound in some, but absent or 
mild in others, and can be purely conductive, purely sensorineural, or mixed [18,41]. 
Increased intracranial pressure is a rare complication of VBD [42]. As mentioned 
above, patients with VBD do not have syndactyly, possibly because the deleted 
SOST enhancer element does not regulate embryonic SOST transcription[32]. It is 
noteworthy that apart from the characteristic skeletal changes, the general health of 
patients with sclerosteosis and VBD is otherwise very good [17,19]. Remarkably the 
excessive bone formed in sclerosteosis and VBD is of very good quality, with patients 
sustaining no fractures even after severe trauma [17,41].  
Tabel 1. Characteristics of Sclerosteosis and van Buchem disease
Sclerosteosis van Buchem disease
Genetic defect Mutation in SOST gene 52 kb deletion downstream 
of SOST
Pattern of inheritance Autosomal recessive Autosomal recessive
Stature Tall Normal
Facial distortion Severe Moderate-severe
Syndactyly Common Absent
Facial palsy Common Common





Pathophysiologically, van Buchem had already suggested some fifty years ago that 
the disease may be caused by excessive bone formation, rather than decreased 
bone resorption, as is the case in osteopetrosis [19]. Excessive bone formation has 
indeed been histologically demonstrated in bone biopsies obtained from patients 
with sclerosteosis [35,37] and biochemically by measurements of markers of bone 
turnover in patients with VBD [19,43] and sclerosteosis [35-37]. Consistent with 
the identified genetic defect, no sclerostin was detected immunohistochemically in 
osteocytes of patients with either sclerosteosis [4] or VBD [14]. Particularly interesting 
is the finding of a normal pattern of bone markers during growth in these patients, 
increasing during childhood and adolescence, but declining after cessation of the 
growth spurt to levels around the upper limit of the adult reference range [35,42] 
(figure 5). No abnormalities have been reported in serum calcium, phosphate and 
parathyroid hormone (PTH) concentrations [18,36,37] in either disease. There were 
no abnormalities in the pituitary hormonal axis when tested in a small number of 
patients with sclerosteosis [36]. 
Figure 5. Sequential measurement of serum alkaline phosphate activity (AP) in U/l, and urinary 
hydroxyproline to creatinine ratio (OHP/Cr) in μmol/mmol in a patient with van Buchem disease 
over a 10-year period. Interrupted lines indicate the upper limit of the normal range.
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Skeletal radiographs show generalized hyperdensity and increased endosteal thickening 
of the tubular bones, similar in patients with sclerosteosis and VBD [19,41,44]. These 
changes are reflected in measurements of bone mineral density (BMD) which is 
greatly  increased at the hip and the spine with z-scores sometimes exceeding +10. 
On CT-scan obliteration of neural foramina, which can be decreased to less than 1 
mm, is a common finding and the jugular canal was narrowed in a few cases [37,45]. 
In both sclerosing dysplasias radiographic changes usually become evident at the 
end of the first decade and progress up to the third decade of life when they appear 
to slow, at least in patients with sclerosteosis [34], Van Hoenacker and colleagues 
showed, however, progressive radiographic changes in the metacarpals of patients 
with VBD with ageing [41]. 
Treatment of sclerosteosis and VBD
There is to date no specific therapy available for the management of patients with 
sclerosteosis and VBD which remains so far largely symptomatic. Decompressive 
surgery may be needed to free entrapped nerves, and hearing aids can help to improve 
hearing. In a patient with a severe case of VBD the insertion of a ventriculo-peritoneal 
drain led to a reduction in intracranial pressure and improvement of symptoms [42] 
(figure 6). In sclerosteosis, placement of a ventriculoperitoneal or lumboperitoneal 
shunt do not give satisfactory results, in contrast to the improvement following 
anterior and/or posterior craniotomy [46]. We recently reported that glucocorticoids 
which decrease bone formation by reducing the number and function of osteoblasts 
may be a useful adjunct in the management of patients with severe disease [42]. 
Figure 6. CT scan of the skull of a 
patients with VBD, demonstrating 
severe thickening of the calvaria and 
presence of ventricular liquor drains 




Measurement of circulating sclerostin
Assays for the measurement of sclerostin in serum of humans have recently become 
available. Using an assay developed by MSD (Gaithersburg, Maryland, USA) we could 
not detect (<1 pg/ml) any sclerostin in the serum of 19 patients with sclerosteosis. 
In contrast, sclerostin was detectable in serum of 77 healthy men and women tested. 
Serum samples from 7 patients with sclerosteosis were also measured with another, 
frequently used commercially available assay (Biomedica, Vienna, Austria). In 4 of 
the 7 patients no sclerostin was detected, while the protein was detectable in the 3 
other with values overlapping with reported low normal values [47-49].  We have 
further validated the MSD assay by epitope mapping, and we tested the reactivity 
of sclerostin fragments of different lengths in both the MSD and Biomedica assay. 
These fragments consisted of the 3 loops without the N- and C-terminus, the 1st and 
2nd loop without the N- and C-terminus, and the 3rd loop alone (figure 7A). High 
concentrations of the fragments (10ng/ml) were not detected by the MSD assay, 
while all were detected by the Biomedica assay (figure 7B). 
Figure 7. Measurement of fragments of sclerostin molecule using 2 different commercially 
available sclerostin assays.
A: Simplified representation of the 
sclerostin molecule. Sclerostin is 
a glycoprotein consisting of 190 
residues, which form a 3 loop like 
structure, with a cystine knot 
(dotted line) at the base [50,51]. 
The 3rd loop is considered to be the 
binding site to LRP5, while the 2nd 
loop was found to be the binding site 
of an inhibiting monoclonal antibody 
against sclerostin [51], implying an 
important function for this loop. 
The long C- and N-termini are also 
of importance for sclerostin action, 
for a sclerostin variant lacking only 
the C- and N- terminus had reduced 
activity [50].
B: detection of sclerostin fragments 
of different length by the MSD and 
Biomedica assay.
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These findings illustrate the difficulties in the interpretation of data from different 
assays which do not detect the same sclerostin forms, as also demonstrated by McNulty 
et al [52]. These authors showed that sclerostin values measured with the Biomedica 
assay correlated poorly with those measured with another commercial assay (TECO, 
Sissach, Switzerland). Until more is known about the secreted, circulating as well 
as bioactive forms of sclerostin, caution is called for in the clinical interpretation of 
results of circulating sclerostin. 
Factors affecting the synthesis of sclerostin
In animal studies, mechanical loading of bone has been shown to stimulate the 
expression of SOST and sclerostin in osteocytes while unloading had the opposite 
effect [53,54]. Consistent with these findings, patients immobilized after a stroke, and 
thus deprived from mechanical load, were shown to have increased serum sclerostin 
levels, which were negatively correlated with the bone formation marker serum bone 
specific alkaline phosphatase [55]. However, a more recent study of immobilized 
patients due to spinal cord injury reported opposite results and it was suggested 
that mechanical unloading may have different, time-dependent, effects on sclerostin 
production [56]. 
Hormonal factors have also been shown to modulate the synthesis of sclerostin 
both in animals and humans. In animals, continuous [57] or intermittent [58] 
administration of PTH downregulates SOST expression and sclerostin synthesis, and 
serum sclerostin levels are decreased in patients with primary hyperparathyroidism, 
increasing after successful parathyreoidectomy [59]. In addition, treatment of 
postmenopausal women with teriparatide for 14 days were associated with significant 
decreases in serum and bone marrow levels of sclerostin [60]. These results suggest 
that the anabolic effect of PTH on bone is exerted, at least in part, by a decrease 
in the production of sclerostin. Recent studies have also indicated that estrogens 
may also influence sclerostin synthesis. Postmenopausal women have been reported 
to have higher circulating sclerostin levels than premenopausal women, these were 
negatively associated with bone formation markers [48],  and decreased by estrogen 
replacement therapy [47]. Estrogen deficiency may, therefore, adversely affect the 
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skeleton not only by increasing bone resorption but also by directly reducing bone 
formation by increasing sclerostin synthesis, thus, further deteriorating the imbalance 
between bone resorption and bone formation which is the pathophysiological basis 
of postmenopausal osteoporosis. In contrast, testosterone replacement therapy  was 
reported to increase serum sclerostin levels in hypogonadal men [47].  
Alterations in sclerostin synthesis may also be involved in the pathogenesis of bone 
lesions in inflammatory bone and joint disorders. The pro-inflammatory cytokines 
tumor necrosis factor (TNF) and TNF-related weak inducer of apoptosis (TWEAK) 
were reported to upregulate SOST expression in vitro and ex vivo [61]. Patients with 
ankylosing spondylitis have also been reported to have lower serum sclerostin levels 
compared to healthy subjects and to patients with rheumatoid arthritis and sclerostin 
levels were found to be associated with the formation of new syndesmophytes [62]. 
Sclerostin expression was also greatly reduced in joints of patients with ankylosing 
spondylitis compared to those of patients with rheumatoid arthritis or osteoarthritis. 
These results, suggest a specific alteration of the function of osteocytes in patients 
with ankylosing spondylitis.  Therapeutic agents known to have deleterious effects 
on bone by increasing bone loss and fracture risk, such as glucocorticoids and 
thiazolidinediones, were also reported to upregulate SOST expression in osteocytes 
in vitro [63,64] 
Sclerostin as a new therapeutic target for the management 
of osteoporosis
The restricted expression of sclerostin to the skeleton and its extracellular activity, 
made this protein an attractive candidate for the development of a new bone forming 
therapy for the management of osteoporosis. This approach was further supported 
by the gene-dose effect suggested by findings in heterozygous carriers of sclerosteosis 
who demonstrate  decreased serum sclerostin levels associated with increased levels 
of P1NP [35] and high normal or increased BMD [65] without any clinical symptoms, 
signs or complications of sclerosteosis. Over the past few years, neutralizing 
antibodies against sclerostin (Scl-ab) were developed and tested in several animal 
models. When given to overiectomized rats, an antibody significantly increased the 
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rate of bone formation at all skeletal envelopes, increased bone mass and improved 
bone strength [66]. The Scl-ab, importantly, also clearly increased bone formation in 
the periosteum, a site hardly affected by current treatments of osteoporosis, while 
it appeared to decrease bone resorption. When given to nonhuman primates Scl-ab 
dose-dependently increased bone formation which was associated with increases in 
bone mass and strength [67]. In a Phase 1 clinical trial a single subcutaneous or 
intravenous injection of Scl-ab administered to healthy men and women led to a 
rapid and dose-dependent increase in serum P1NP, and to an increase in BMD at the 
spine and hip within 3 months of administration [68]. Consistent with findings from 
animal studies, the administration of the Scl-ab also decreased serum CTX, a marker 
of bone resorption. Phase 2 clinical studies of the efficacy and tolerability of SCL-ab 
are currently underway.
 
Treatment with Scl-ab  has also been shown to prevent inflammation- induced bone 
loss in mice with chronic colitis and glucocorticoid-induced bone loss in mice on 
dexamethasone treatment [69,70]. The effect of Scl-ab on fracture healing was also 
recently studied in animal models and was shown to increase bone mass and strength 
at the site of fracture, to improve callus formation and maturation, and to reduce the 
incidence of non-union [71]. A Phase 2 clinical study of the effect of Scl-ab on fracture 
healing is in last stages of completion.
Conclusion
 
The story of sclerostin is a true example of how genetic studies of rare diseases 
can lead to ground breaking new insights into molecular pathways, and how the 
understanding of the pathophysiology of a disorder may lead to the development 
of new therapies for another. Sclerostin has been shown to play a key role in bone 
metabolism, and sclerostin inhibition by neutralizing antibodies might prove to be 
a very successful therapy in restoring bone mass in low bone mass disorders such as 
osteoporosis. Unraveling the role of sclerostin in the pathophysiology of the disabling 
and sometimes life-threatening disorders sclerosteosis and VBD has, unfortunately, 
not yet led to the development of a satisfactory therapy for their management. 
Effective therapies to control the unrestrained bone formation associated with these 
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Sclerostin is a glycoprotein secreted by osteocytes (1) (Figure 1), which acts locally 
on cell membrane receptors of osteoblasts (2) and in an autocrine fashion on other 
osteocytes (3). Sclerostin is released in the circulation and is detected in serum and 
plasma (4). There is a strong relationship between circulating and bone marrow plasma 
levels of sclerostin consistent with the findings that osteocytes are the major source 
of sclerostin production and, therefore, the sclerostin present in peripheral blood 
[5]. There are currently 3 commercially available assays for sclerostin. Two of these, 
manufactured by Biomedica and TECOmedical gruppe (TECO), are conventional 
enzyme-linked immunoabsorbent assays (ELISA), based on chemiluminescence. 
The third assay, manufactured by Meso Scale Discovery (MSD) is an ELISA based 
on electrochemiluminescence. In all studies reported in this thesis sclerostin was 
measured by the MSD sclerostin assay (MSD® 96-well MULTI-ARRAY® Human 
Sclerostin Assay). Prior to these studies we examined the performance of this assay 




Figure 1. Structure of sclerostin
(green =  human sclerostin; blue  = mouse sclerostin)
Chapter 2
37
Description of the MSD sclerostin assay
In the MSD assay, 96 well plates are coated with a purified goat polyclonal antibody 
raised against the full murine sclerostin molecule as capture antibody; a polyclonal 
goat anti-human sclerostin is used as detection antibody. The detection antibodies are 
tagged with electrochemiluminescent labels, which emit light when electrochemically 
stimulated. The detection process is initiated at electrodes located in the bottom of 
the microplates. Background signals are minimal because the stimulation mechanism 
(electricity) is decoupled from the signal light [http://www.mesoscale.com/
CatalogSystemWeb/WebRoot/technology/ecl/walkthrough.htm. accessed January 
2012 (8)]. The sclerostin standard for the assay was produced in an NS0-derived 
myeloma cell line, and the purity was checked by SDS–PAGE gel with silver stain.
Characterization of the MSD sclerostin assay
Bioavailability of circulating form(s) of sclerostin is currently unknown and the 
specificity of commercial assays for different domains of the molecule has not been 
reported. To assess the specificity of the MSD assay for the sclerostin molecule, we 
performed a series of experiments. 
First, to validate the sclerostin standard used in this assay, we compared it to that 
of recombinant sclerostin prepared by the University of Würzburg, Germany, kindly 
provided by Professor Thomas Mueller within the TALOS research consortium. This 
recombinant sclerostin was produced in an E.Coli strain, and the protein concentration 
was accurately determined by spectrophotometry. Serial dilutions (10 to 1000 pg/ml) 
of both these sclerostin preparations were measured. Values of the two peptides were 
highly concordant at every concentration. The mean ratio of the concentrations was 
1.02 (range 0.8-1.3) (Figure 2). 
Second, to characterize the specificity of the antibodies used in the assay, we performed 
epitope mapping of the polyclonal detection and capture antibodies according to 
Pepscan’s Epitope Mapping Technology [kindly performed by Jaap Willem Back 
and Peter Timmerman of Pepscan Therapeutics (Lelystad, the Netherlands) within 
the TALOS research consortium]. Pepscan’s Epitope Mapping Technology uses 
microarrays of overlapping peptides, covering the complete sequence of a given 
protein. Antibody binding studies subsequently identify the peptides representing the 
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protein interaction of interest. (http://www.pepscantherapeutics.com/technology/
epitope-mapping). The epitope mapping revealed two binding sites of the capture 
antibody for human sclerostin, one on the N-terminus and one on the distal end of 
the C-terminus. For the detection antibody there were three apparent epitopes; at 
the N-terminus, at the 3rd loop, and at the C-terminus of the protein (Figure 3). We 
validated these results by assessing the reactivity of sclerostin fragments of different 
sizes (provided by Jaap Willem Back of Pepscan Therapeutics). We tested three 
different fragments comprising the three loops without the N- and C-terminus; the 
first and third loop without C- and N-terminus; and the second loop alone (Figure 4). 
All fragments were added at high concentrations (10 ng/ml). As expected from the 
epitope mapping, all fragments were undetectable, suggesting that the assay detects 
the whole sclerostin molecule.
Third, to assess the specificity of the assay for sclerostin we tested serum samples 
of 3 patients with sclerosteosis. These patients do not synthesize sclerostin, due to 
a genetic defect in the gene encoding sclerostin. As expected, no sclerostin could be 
detected in the serum of all 3 patients. In contrast, sclerostin was detected in serum 
of all 77 healthy individuals tested. These results demonstrate that the MSD assay 
is highly specific for the sclerostin protein and, hence, suitable for clinical studies.
 
Figure 2. Comparison of serial dilutions of the Meso Scale Discovery (MSD) sclerostin 
standard with recombinant sclerostin prepared  by the University of Wurzburg (UoW). 
When measured with the MSD sclerostin assay, the  output signal of both sclerostin 
preparations were highly concordant at all concentrations. 
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Figure 3. Epitope mapping of the MSD capture antibody (upper panel) and detection antibody 
(lower panel). Spikes in the base line represent binding affinity of the antibodies for the sclerostin 
molecule. 
Figure 4. Measurement of fragments of the sclerostin molecule using the MSD sclerostin assay.
A: Simplified representation of the sclerostin molecule.




Performance of the MSD sclerostin assay
The performance of the MSD sclerostin assay was assessed according to international 
guidelines (6;7) and results are summarized in Table 1. The relationship between 
measured sclerostin values of serially diluted samples and the outcome signal was 
linear (r=0.998). The lower limit of detection, determined by the mean +2 standard 
deviations of the output signal of 10 blank samples, was 1 pg/ml. 
Within-run precision and between-run precision were determined at 5 different 
concentrations spanning the detection range (10, 50, 100, 1000, and 10,000 pg/
ml). The within-run precision was less than 6% at all concentrations. Between-run 
precision was below 10% at 50, 100 and 1000 pg/ml, but somewhat higher at 10 pg/
ml (13%) and 10,000 pg/ml (15%). In 3 serum samples measured over 10 runs the 
between-run precision was less than 7% (Table 2). The recovery of exogenously added 
sclerostin (65, 125 and 250  pg/ml)  to serum samples was 82%-93%.
Test Results
Lower limit of detection 1 pg/ml
Detection range 1-10,000 pg/ml
Inter assay precision (CV)a 10 %
Intra assay precision (CV) 6 %
Recoveryb 82 -92 %
Table 1. Performance of the MSD sclerostin assay
CV= coefficient of variation ([standard deviation/mean]*100)                                              
a excluding samples at the end of the spectrum of the detection range (10 and 10.000 pg/ml)    
b recovery of exogenously added sclerostin to serum sample





1 20.98 1.54 7.4
2 37.70 2.32 6.2
3 106.34 7.89 7.4
Table 2. Inter assay precision assessed in 3 serum samples measured in 10 different runs
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To assess the stability of the sclerostin protein in serum subjected to repeated 
freezing and thawing, we made aliquots of freshly drawn serum samples. One aliquot 
was thawed and frozen for 7 subsequent runs, and compared to a fresh aliquot during 
each run. For each run, measured sclerostin values in the previously thawed aliquots 
were highly concordant with those of the single thawed aliquots (86-98%); there was 
no trend for increasing or decreasing sclerostin values in subsequent runs. 
The stability of measured sclerostin in serum kept at room temperature (20ºC) was 
determined by storing aliquots of 3 different serum samples at room temperature for 
8, 24 or 48 hours. Aliquots were then frozen and were measured in the same assay and 
compared to aliquots immediately frozen after blood collection. Results are shown in 
Table 3. After 8 hours at room temperature, serum sclerostin levels decreased by 60% 
in one sample whereas these were 94% and 120% of levels measured in the immediately 
frozen sample, in the other two samples. After 24 hours, measured sclerostin levels 
decreased by 33%-68% of the original levels in all 3 samples and decreased further 
slightly after 48 hours at room temperature (23%-65%). For clinical studies it is, 
therefore, essential to store serum in the deep freeze soon after its separation from 
blood, a procedure that was followed in all studies reported in this thesis.
The effects of different sample media, serum or EDTA plasma, on measured sclerostin 
values was determined by measuring sclerostin levels in simultaneously drawn serum 
and EDTA plasma samples from 26 subjects. Sclerostin levels were higher in plasma 
by a factor of 3.6 ± 1.0 compared to those measured in serum, but levels in serum 
and plasma were highly correlated (r=0.91, p=0.001) (Figure 5). Similar findings 
have been previously reported for heparinized plasma and were attributed to the 
formation of complexes of sclerostin with other proteins in serum. (4). It should be 
sample 1 2 3
frozen 20,38 12,89 25,32
Period at 20ºC            8h 12,22 (60%) 15,51(120%) 23,75 (94%)
24h 6,77 (33%) 6,96 (54%) 17,13 (68%)
48h 4,60 (23%) 5,48 (43%) 16,47 (65%)
Table 3. Stability of  sclerostin in serum kept at room temperature (20ºC)
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mentioned, however, that the sclerostin molecule has a binding site for heparin (9). 
Finally, to assess the day to day variation in sclerostin levels in an individual, we 
obtained non-fasting serum samples from 7 healthy subjects at the same time of 
the day on 3 separate occasions, at 3 to 4 day intervals. All samples were measured 
in the same run. Individual sclerostin levels at all 3 time points are depicted in 
Figure 6. Within subject variation, described as the coefficient of variation (standard 
deviation/mean*100) of 3 measurements, ranged between 9% and 29 % (mean 19%).
Figure 5. Relationship between plasma (EDTA) and serum levels of sclerostin in blood samples 
of 26 subjects (r=0.91, p<0.001). Sclerostin levels were 3.6 ± 1.0 times higher in plasma 
compared to serum samples.
Figure 6. Within subject (n=7) variation in circulating sclerostin levels 
Blood samples were collected at 3 different time point, 3 to 4 days apart. 




The epitopes of the capture and detection antibodies, and the absence of detection 
of sclerostin fragments of different length by the MSD sclerostin assay, suggests that 
this assay is specific for the entire sclerostin molecule, while the undetectable levels 
in all tested patients with sclerosteosis underscores its specificity for sclerostin and 
rules out interference of other proteins in the assay. The assay has a good precision 
and a wide detection range suitable for use in clinical studies. Furthermore, repeated 
freezing and thawing of samples did not change measured values suggesting that the 
molecule is stable. However, if samples remain at room temperature beyond 8 hours 
lower values may be measured. There is a clear difference in measured sclerostin 
values in serum and EDTA plasma. Although values in serum and plasma were 
highly concordant this should be considered in clinical studies and a new reference 
range should be obtained for plasma values (see Chapter 6). Finally, the large intra 
individual variation (19%), should be considered in studies evaluating sequential 
changes of circulating sclerostin in humans. 
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Abstract
Sclerosteosis is a rare bone sclerosing dysplasia, caused by loss-of-function mutations 
in the SOST gene, encoding sclerostin, a  negative regulator of bone formation. 
The purpose of this study was to determine how the lack of sclerostin affects bone 
turnover in patients with sclerosteosis, and to assess whether sclerostin synthesis is 
decreased in carriers of the SOST mutation, and if so, to what extent this would 
affect their phenotype and bone formation. We measured sclerostin, P1NP, and CTX 
in serum of 19 patients with sclerosteosis, 26 heterozygous carriers of the C69T 
SOST mutation, and 77 healthy controls. Chips of compact bone discarded during 
routine surgery were also examined from 6 patients and 4 controls. Sclerostin was 
undetectable in serum of patients, but was measureable in all carriers (mean:15.5pg/
ml; 95%CI:13.7-17.2pg/ml), in whom it was significantly lower than in healthy 
controls (40.0pg/ml; 36.9-42.7pg/ml; p<0.001). P1NP levels were highest in patients 
(153.7ng/ml;100.5-206.9ng/ml; p=0.01 vs carriers, p=0.002 vs controls), but carriers 
also had significantly higher P1NP levels (58.3ng/ml; 47.0-69.6ng/ml) than controls 
(37.8ng/ml; 34.9-42.0ng/ml;p=0.006). In patients and carriers, P1NP levels declined 
with age, reaching a plateau after the age of 20 years. Serum sclerostin and P1NP 
were negatively correlated in carriers and age- and gender-matched controls (r= 0.40, 
p=0.008). Mean CTX levels were well within the normal range and were not different 
between patients and disease-carriers after adjusting for age (p=0.22). 
Our results provide in vivo evidence of increased bone formation caused by the absence 
or decreased synthesis of sclerostin in humans. They also suggest that inhibition of 
sclerostin can be titrated, since the decreased sclerostin levels in disease carriers did 
not lead to any of the symptoms or complications of the disease but had a positive 





Sclerosteosis is a rare, autosomal recessive bone sclerosing dysplasia characterized by 
generalized osteosclerosis (1). It is caused by loss-of-function mutations in the SOST 
gene encoding for sclerostin (2-4), a protein produced in bone by osteocytes (5) which 
decreases bone formation by inhibiting the Wnt signalling pathway in osteoblasts 
(6,7). In patients with sclerosteosis the lack of sclerostin leads to unrestrained bone 
formation resulting in generalized osteosclerosis.
The clinical manifestations of sclerosteosis  have been well described since it was first 
identified in 1958 (8) and include cranial nerve deficits and increased intracranial 
pressure due to excessive growth of the skull bones (9,10). Bone mineral density 
(BMD) is markedly increased at the spine and the hip (11) but data on the rate of 
bone turnover are scarce in these patients.  Interestingly, heterozygous carriers of the 
SOST mutation have high normal or increased BMD (11), suggesting that having 
one affected allele of the SOST gene would also have an effect on sclerostin synthesis, 
albeit milder than was observed in the homozygous state. Whether this may also be 
associated with clinical manifestations has not been studied systematically.     
To address these questions we conducted a study in a cohort of patients with 
sclerosteosis and their relatives who were heterozygous carriers of the SOST mutation, 
with the following specific aims: first, to determine how the lack of sclerostin affects 
parameters of bone turnover in patients with sclerosteosis, and second to assess 
whether sclerostin synthesis is decreased in carriers of the SOST mutation and if so, 
to which extent this would affect their phenotype and bone turnover. 
Subjects and Methods
Nineteen South African patients with sclerosteosis and 30 mostly first degree relatives 
living within a 250 km radius from Johannesburg were invited to participate in our 
study. None of the patients or relatives studied used any drugs that could affect 
bone metabolism. One patient was on long-term treatment with thyroid replacement 
therapy for hypothyroidism. 
Physical examination, focusing on clinical features of sclerosteosis and on neurological 
deficits, was conducted at the Ear-Nose-and-Throat Department of the Flora Clinic 
in Johannesburg, or at the patients’ home by A.v.L. and H.H. Since patients with 
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sclerosteosis are descendants of Dutch settlers, and because South African normative 
data are lacking, height z-scores were calculated relative to Dutch normative data, 
using Growth Analyzer 3.5 (Dutch Growth Foundation, Rotterdam, Holland). 
Results of hearing tests were obtained from the patient’s hospital records.  Non-
fasting blood samples were collected as convenient, but samples from patients and 
their family members were collected at the same time of the day. Full blood samples 
and separated serum and plasma were frozen and transported to the Netherlands on 
dry ice for biochemical analysis and DNA extraction. 
The study was conducted according to the principles of the Declaration of Helsinki, 
was approved by the Medical Ethical Committee of the Leiden University Medical 
Center and informed consent was obtained from all subjects included in the study.
DNA analysis
DNA was isolated from full blood samples using the Insorb® spin blood maxi 
kit (Invitek GmbH, Berlin, Germany). The first exon of the SOST gene was 
replicated by PCR, using primers 5’-AAGGAACTTGCCCAAGATGA-3’ and 
5’-AAGGCTCGAGCCCAAGATGA-3’. PCR products were purified with microspintm 
S-400 HR columns (GE Healthcare, Buchinghamshire, UK) and sent to the Leiden 
Genome Technology Centre for sequencing. DNA sequences were analysed with 
Chromas 2.33 (Technelysium Pty Ltd), focusing on the presence of a single cysteine 
to tyrosine substitution 69 base pairs downstream of the predicted translation 
initiation site (C69T), previously found to be the underlying mutation in South 
African patients with sclerosteosis (3). 
Serum Biochemistry 
All biochemical measurements were performed at the Clinical Chemistry Laboratory 
of the Leiden University Medical Center, Leiden.  Serum calcium adjusted for 
albumin, phosphate, and creatinine were measured by semi-automated techniques. 
Alkaline phosphatase (ALP) was measured using a fully automated P800 modulator 
system (Roche BV, Woerden, Holland). P1NP and β-CTX were determined by the 
E-170 system (Roche BV, Woerden, Holland). 25-hydroxyvitamin D (25-OHD) was 
measured by the LIAISON® 25-OH Vitamin D TOTAL assay (DiaSorin S.A./N.V., 




Sclerostin was measured in serum by an electrochemiluminescense assay (MSD® 
96-well MULTI-ARRAY® Human Sclerostin Assay, Meso-Scale Discoveries, 
Gaithersburg, Maryland, USA) as described previously (12). The assay is very 
sensitive (detection limit: ±1pg/ml), with a broad detection range (1 to 10,000 pg/
ml), and an intra-assay precision of 6% and an inter-assay precision of 10%.  The 
recovery of sclerostin in serum spiked with sclerostin 250, 125, and 65 pg/ml was 
82%-93%.  
Sclerostin is a glycoprotein containing 190 residues, which form a three loop-like 
structure, with a cystine knot at the base and long, highly flexible C- and N-terminal 
regions (13). Bioavailability of circulating form(s) of sclerostin is currently unknown 
and the specificity of commercial assays for different domains of the molecule has 
not been reported. We performed, therefore, additional experiments to obtain more 
insight into the specificity of the MSD assay for sclerostin.
First, to validate the sclerostin standard used in this assay, we compared it to that 
of recombinant sclerostin prepared by the University of Würzburg, Germany, kindly 
provided by Professor Thomas Mueller within the TALOS research consortium. This 
recombinant sclerostin was produced in an E. Coli strain, and the protein concentration 
was accurately determined by spectrophotometry. Serial dilutions (10 to 1000pg/ml) 
of both these sclerostin preparations were measured. Values of the two peptides were 
highly concordant at every concentration. The mean ratio of the concentrations was 
1.02 (range 0.8-1.3). Second, to characterize the specificity of the antibodies used in 
the assay, we performed epitope mapping of the polyclonal detection and capture 
antibodies according to Pepscan’s Epitope Mapping Technology [kindly performed 
by Jaap Willem Back and Peter Timmerman of Pepscan Therapeutics (Lelystad, the 
Netherlands) within the TALOS research consortium]. Pepscan’s Epitope Mapping 
Technology uses microarrays of overlapping peptides, covering the complete sequence 
of a given protein. Antibody binding studies subsequently identify the peptides 
representing the protein interaction of interest. (http://www.pepscantherapeutics.
com/technology/epitope-mapping). The epitope mapping revealed two binding sites 
of the capture antibody for human sclerostin, one on the N-terminus and one on the 
distal end of the C-terminus. For the detection antibody there were three apparent 
epitopes; at the N-terminus, at the 3rd loop, and at the C-terminus of the protein. 
We further validated these results by assessing reactivity of sclerostin fragments of 
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different sizes (provided by Jaap Willem Back of Pepscan therapeutics). We tested 
three different fragments comprising the three loops without the N- and C-terminus; 
the first and third loop without C- and N-terminus; and the second loop alone.  All 
fragments were added at high concentrations (10 ng/ml). As was expected from the 
epitope mapping, all fragments were undetectable, suggesting that the assay detects 
the whole sclerostin molecule.
Serum sclerostin, and bone turnover marker values, were compared with those 
obtained in a cohort of healthy volunteers, who were used as controls as previously 
described (12). This group consisted of 77 healthy volunteers, 30 males and 47 
females, with mean age 50.3 years (range: 20-77 years), and mean BMI of 25.2 kg/m². 
All had normal serum calcium and phosphate concentrations, normal renal function 
and biochemical markers of bone turnover.
Bone biopsies
Chips of compact bone, obtained from 6 patients with sclerosteosis (4 reported here), 
on a different occasion during surgical procedures, and from 4 controls subjects 
were examined. The samples were fixed in 10% neutral buffered formalin and were 
embedded in methyl methacrylate without prior decalcification (14,15). Ten micron 
sections were cut by a Jung Polycut E microtome (Leica, Milton Keynes, UK) 
and stained using solochrome cyanine R and Goldner’s protocols (15).  Images for 
the quantification of bone remodeling parameters were acquired under bright field 
illumination at x5 objective magnification using Surveyor software (Objective imaging 
Ltd, Cambridge, UK).  The samples were essentially compact bone which was being 
remodeled in a manner similar to cortical bone, so that assessment of bone formation 
and resorption was done in the same way as that reported by Bell and colleagues 
(15).  Canals within the bone were denoted as undergoing formation (presence of 
an osteoid seam) or resorption (presence of a crenelated surface) and the data were 
expressed as a proportion of the total number of canals within the specimen.
Statistical analysis
Statistical analysis was performed using the SPSS 17.0 software (SPSS Inc. Chicago, 
USA). Group differences in levels of sclerostin and other biochemical markers were 
assessed by ANOVA. Because of inequality in sample sizes, a Games-Howell post-hoc 
test was used. To adjust for effect of age on P1NP levels, we also matched carriers to 
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healthy controls according to gender and age (within five years).  Correlations between 
sclerostin and bone turnover markers were determined by Pearson’s correlation tests. 
P1NP and Sclerostin data were log transformed because of skewness. A p-value below 
0.05 was considered significant.
Results
Subjects 
The diagnosis of sclerosteosis was confirmed in all 19 patients studied by DNA analysis, 
on the basis of the demonstration of a C69T substitution in both alleles of the SOST 
gene. Of the 30 relatives, 26 were heterozygous carriers of the C69T mutation and 
were included in the analysis. Median age of the patients was 23 years (range 9 to 70 
years), and of the carriers 44 years (range 13 to 70 years). Characteristics of patients 






male:female 11:8 7:19 0.16
Age (years) 28.32 ± 15.0 39.9 ± 15.0 0.014
Height (cm) 179.8 ± 12.0 164.0 ± 37.0 0.100
Height z-score (sd) +0.83 ± 0.73 -0.48 ± 0.89 <0.001
BMI (kg/m²) 25.6 ± 5.7 25.7± 5.3 0.93
Calcium (mmol/l) 2.33 ± 0.07 2.27 ± 0.11 0.06
Phosphate (mmol/l) 1.37 ± 0.32 1.20 ± 0.32 0.10
25(OH)D (nmol/l) 48.9 ± 13.1 41.6 ± 15.0 0.10
Creatinine (μmol/l) 62.2 ± 20.4 55.2 ± 12.1 0.20
Table 1. Characteristics and parameters of calcium metabolism in patients with sclerosteosis 
and heterozygous disease carriers




At the time of the study 3 of the 19 patients had symptoms related to increased 
intracranial pressure in the form of severe and persistent headaches, worse in the 
morning and associated with dizziness and nausea. Two of these 3 patients had 
already undergone decompressive surgery to relieve the increased intracranial 
pressure. Thirteen of the remaining 16 patients had undergone decompressive surgery, 
10 after experiencing symptoms of increased intracranial pressure, and 3 following 
a diagnosis of increased intracranial pressure on routine screening. Decompressive 
surgery consisted of anterior, and/or posterior craniotomy, as described previously 
(16). The median age at which this procedure was performed was 15 years. Of the 7 
patients who had undergone this procedure at a younger age, 4 (57%) had to be re-
operated because of recurrence of signs of increased intracranial pressure after 2 to 
11 years. Of the 8 patients in whom the operation was performed after the age of 15 
years, only 1 (13%) patient had to be re-operated after an interval of 2 years.
The majority of patients (89%) had experienced recurrent episodes of facial palsy, 
usually occurring before the age of 4 years, although unilateral facial paresis was 
already present at birth in one patient. Surgical decompression of the facial nerve was 
conducted in all cases, with the unaffected side also decompressed prophylactically. 
Despite these interventions, facial palsy recurred in 6 of the previously operated 
cases.  Hearing loss was present in all cases, had been recognized in early childhood 
and progressed into adulthood. Operations to improve hearing, such as widening of 
the external bony ear canal, or freeing of fixed ossicles, had been performed in 13 
patients. Eleven patients used hearing aids.  Other complaints associated with cranial 
nerves compression were decreased sensation of the face (trigeminal nerve) in two 
cases, and a visual field defect in one eye in one patient (optic nerve). None of the 
patients reported sustaining a bone fracture. 
Overview of the medical history of the whole group provided insight into the natural 
history of the disorder. Disease manifestations first appear during childhood and 
adolescence and progress through to the third decade of life appearing to stabilize 
thereafter. In the majority of patients no recurrence or progression of symptoms were 
observed after the age of 25 years. 
On clinical examination, the majority of patients were of tall stature. The average 
height of adult male patients was 190.6 cm, and of adult females 175.7 cm. Mean 
weight and body mass index (BMI) were respectively 104.4 kg and 28.8 kg/m2 for 
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adult males, and 73.7 kg and 24.7 kg/m2 for adult females. Mean height z-score of 
patients was above zero, and was significantly higher than that of their relatives 
(p<0.001) (Table 1).  Patients had a sclerosteosis phenotype, as previously described, 
of variable degree of severity. The facial deformities of bossing of the forehead and 
enlargement of the mandible were observed in 47% and 68% of subjects, respectively, 
and had generally developed by the time puberty was reached. Although these 
features were not present in the two youngest patients, both 9 years old, they were 
already clearly noticeable in 2 young male patients, aged 12 and 13 years old. Six 
patients had undergone corrective surgery of the mandible. One of these patients 
needed a second corrective surgery 7 years later due to further enlargement of the 
mandible. Syndactyly of fingers or toes was present in 52% of the cases. All but one 
of the remaining patients did, however, display other digit abnormalities, such as nail 
dysplasia or radial deviation of the phalanges.
On neurological examination movement of the facial muscles was impaired in 73% of 
patients, bilateral in 52% of these cases, and of moderate (House Brackmann score: 
Grade III) to moderately severe (Grade IV) degree. Previously performed hearing 
tests were abnormal in all patients, showing conductive hearing loss of a moderately 
severe (50-70 dB) to severe (70-90dB) grade in all, with an additional sensorineural 
component in 36 % of the cases. In 2 patients hearing loss was complete. Cognitive 
function was normal in all patients. 
None of the carriers reported having any of the above mentioned symptoms and 
none had abnormal findings on clinical examination. Similar to patients, none of the 
studied carriers had ever sustained a fracture.
Serum chemistry
There was no difference in serum calcium, phosphate and 25(OH)D concentrations 
between patients and carriers, and all had normal renal function (Table 1).
Markers of bone turnover
Serum P1NP levels declined with age in both patients and carriers and appeared 
to reach a plateau after the age of 20 years (Figure 1). Thirteen out of 14 adult 
patients (18 years or older) and 7 out of 22 adult carriers had serum P1NP values 
above 65 ng/ml. Because of the clear effect of age on serum P1NP levels and the low 
number of young individuals in the carrier group, we compared serum P1NP between 
Sclerosteosis
56
adult patients and carriers. P1NP levels were significantly different between groups 
(ANOVA: p<0.001). Compared with carriers and controls, patients with sclerosteosis 
had significantly higher serum P1NP values (153.7 ng/ml; 95%CI=100.5-206.9ng/ml; 
p=0.01 vs carriers, p=0.002 vs controls) while carriers (58.3 ng/ml; 95%CI=47.0-69.6 
ng/ml) had significantly higher values than controls (37.8 ng/ml; 95%CI=34.5-41.0 
ng/ml; p=0.006) (see also Figure 2) These differences remained after adjusting the 
P1NP values for age. 
Similar to serum P1NP, serum CTX values declined with age reaching a plateau 
around the age of 20 years (Figure 1). However, in all but one adult patient values 
were lower than 600 pg/ml. There was a difference in mean serum CTX between adult 
patients (213 pg/ml; 95%CI=103-323 pg/ml) and carriers (126pg/ml; 95%CI=84-
167pg/ml, p=0.02), but this was no longer significant after adjusting for age (p=0.22). 
Although absolute values for serum CTX should be interpreted with caution because 
not all samples were obtained in the fasting state, comparison of serum CTX between 
groups is valid, because samples were obtained from patients and carriers under 
identical conditions. Serum P1NP and CTX values were significantly correlated both 
in patients (r=0.86, p<0.001) and carriers (r=0.46, p=0.025).
Figure 1. Relationship between serum P1NP levels and age (left panel) and CTX levels and 
age (right panel) in patients with sclerosteosis and heterozygous disease-carriers.
Closed circles represent homozygous patients, open circles represent heterozygous carriers. 
The dotted lines represent the upper limit of the normal adult reference range 




Serum sclerostin was undetectable in all 19 patients. In contrast, sclerostin was 
measurable in the serum of all carriers, although the mean value (15.5 pg/ml; 95% 
CI=13.4-16.9pg/ml) was significantly lower than that of healthy controls (40.0 pg/
ml; 95%CI=37.2-42.9 pg/ml; p<0.001) (Figure 2), and the difference remained 
significant after adjusting values for age. There was no correlation between serum 
sclerostin and either P1NP or CTX in carriers. However, when values of carriers and 
controls were pooled together, there was a significant negative correlation (r=-0.23, 
p=0.02) between sclerostin and P1NP, which improved further (r=-0.40, p=0.008) 
when carriers were analysed together with age and gendermatched controls (Figure 
3).   
Figure 2. Serum P1NP (left panel) and sclerostin (right panel) levels in healthy controls and 
adult patients with sclerosteosis and heterozygous disease-carriers. 
Bars represent SEM. a: p=0.002; b: p=0.01; c: p=0.006; d: p<0.001
Figure 3. Relationship between serum P1NP and sclerostin levels in age-matched healthy 
controls (open circles) and heterozygous carriers of sclerosteosis (closed circles). r=-0.40, p=0.008
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Histomorphometric analysis of bone remodeling
The results of histomorphometric analysis of bone samples are shown in Table 2. 
Bone from patients with sclerosteosis showed evidence of increased formation in 
that there was a higher proportion of canals with an osteoid seam compared to 
bone from similar sites in control subjects (sclerosteosis: 2.6 to 21.1%; controls: 1.1 
to 3.7%; Table 2).  The proportion of canals undergoing resorption was similar in 
both groups (sclerosteosis: 0.6 to 3.0%; controls 0 to 0.9%). In the patients, as with 
the relationship between serum P1NP and age, bone formation activity appeared to 
reach a peak at puberty. Direct comparison of histomorphometric values is, however, 
not appropriate due to differences in age between patients and controls.






1 Mastoid 37 Female 1/41 (2.4%) 0/54 (0.0%)
2 Mastoid 49 Female 1/37 (2.7%) 0/37 (0.0%)
3 Mastoid 49 Male 1/94 (1.1%) 0/113 (0.0%)
4 Mastoid 64 Male 4/108 (3.7%) 1/117 (0.9%)
Patients
1 Mastoid 4 Male 8/311 (2.6%) 2/347 (0.6%)
2 Mastoid 8 Female 49/654 (7.5%) 9/686 (1.3%)




14 Male 11/52 (21.1%) 2/67 (3.0%)
5 Mastoid 18 Male 7/49 (14.2%) 1/47 (2.1%)
6 Mastoid 43 Male 8/77 (10.4%) 4/107 (0.9%)




Patients with sclerosteosis and heterozygous disease carriers form a unique model to 
study the role of sclerostin on bone metabolism in humans. In this study we show 
that there is a gene-dose effect of the slerosteosis mutation on circulating sclerostin, 
with absent sclerostin in serum of patients and decreased sclerostin levels in disease 
carriers. These differences in circulating sclerostin were accompanied by different 
levels of the bone formation marker serum P1NP between patients, carriers and 
controls. 
The recognition of the role of sclerostin in bone metabolism and the development of 
commercial assays for measuring it in serum, have led to a series of studies that explored 
the association between serum sclerostin and indices of bone metabolism in healthy 
individuals and in patients with various bone disorders (12,17-23). Caution is needed, 
however, in interpreting the results of these studies and in deriving conclusions about 
the pathophysiological significance of observed associations. Sclerostin is produced in 
bone by osteocytes, acts on osteoblasts and is released in the circulation. At present, 
neither the bioactivity of circulating sclerostin nor the specificity of the antibodies 
used in existing assays for the protein are known.  Moreover, there are differences 
in measured values, and reported values obtained with different assays are poorly 
correlated (24). In the present study we used a highly sensitive assay with a very 
low limit of detection and we assessed for the first time its specificity in detecting 
sclerostin. Our findings suggest that this assay detects the whole sclerostin molecule 
rather than circulating fragments, which may be active. The lower values measured 
with this assay compared with those reported with other assays, may be attributed 
to lower detection of protein-bound forms of the protein.  
Previous studies have shown that sclerostin is not expressed by osteocytes of patients 
with sclerosteosis (5) and our data on serum sclerostin are in agreement with these 
findings and the pathogenesis of the disease. We could not detect sclerostin in the 
serum of any patient with sclerosteosis, which provides a powerful negative control 
for the assay we used, supporting its specificity, and suggesting that measured values 
can be of biological significance. Contrary to patients with sclerosteosis, sclerostin 
was detectable in the serum of all carriers of the disease being, however, on average 
60% lower than values measured in healthy controls. These lower circulating levels 
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of sclerostin most likely mirror a decreased synthesis of the protein by the osteocytes 
of these individuals as a result of the affected SOST allele. The reduced synthesis of 
sclerostin in disease carriers affects bone metabolism but is not associated with any of 
the clinical manifestations or complications of sclerosteosis.  The clinical presentation 
of our patients with sclerosteosis is in accordance with earlier descriptions of the 
disease and confirms the high frequency of serious complications resulting from 
entrapment of cranial nerves due to increased bone formation in the skull. Disease 
carriers, however, were symptom-free and there were no clinical signs suggestive of 
any of these complications. This may be due to the lower rates of bone formation of 
carriers compared with patients as evidenced by serum P1NP values.  On the other 
hand, when compared with healthy individuals, disease carriers had higher P1NP 
values and there was a significant negative correlation between serum sclerostin and 
P1NP values. These results help to explain the previously reported high BMD values 
of carriers (11) and minor changes apparent on skull radiographs (25).    In addition, 
they suggest that non-excessive inhibition of sclerostin production may have a 
positive effect on the skeleton without causing any of the complications associated 
with the absence of the protein. Currently inhibitors of sclerostin are being developed 
as potential bone forming treatment for patients with osteoporosis, but values of 
circulating sclerostin and P1NP were not reported (26,27). Our data indicate that 
decreasing the synthesis of sclerostin can have a beneficial effect on the strength of 
the skeleton, as already shown in animal studies (28-30).
An important finding, as also previously noted by Beighton et al. (10), was the 
stabilization of the disease and the dramatic decrease in the frequency of complications 
after the third decade of life suggesting that the rate of bone formation slows down in 
patients with ageing. This hypothesis is supported by the negative correlation between 
age and serum P1NP values and by the histological findings. It is also of interest to 
note that serum P1NP changes follow a normal pattern during growth being high 
in childhood and adolescence and reaching a plateau after completion of growth. In 
addition, the highest bone formation rate, as assessed by histomorphometry, was 
found in a 14-year old patient.  In a previous longitudinal study of a patient with 
the closely related bone dysplasia, van Buchem disease, we showed that biochemical 
markers of bone turnover were always increased for age but followed a normal pattern 
during growth with the highest levels observed during the growth spurt with a decline 
Chapter 3
61
thereafter (31). Taken together, these observations strongly suggest that the skeleton 
of patients lacking sclerostin responds normally to local and systemic signals, as also 
evidenced by the significant relationship between serum P1NP and CTX values.  The 
lack of sclerostin may be also responsible for the patients’ tall stature. Although this 
has been mentioned as a clinical feature of the disease, our study is the first to examine 
this in detail. Sclerostin is expressed by terminally differentiated chondrocytes (32,33), 
which can be regarded as the equivalent to osteocytes in the chondrocyte lineage, and 
canonical Wnt signaling promotes differentiation and maturation of  chondrocytes 
(34). It might, therefore, well be that sclerostin has a similar inhibiting role on Wnt 
signaling in chondrocytes in the growth plate. In sclerosteosis the sclerostin deficiency 
would lead to increased differentiation towards hypertrophic chondrocytes resulting 
in a larger hypertrophic zone in the growth plate and, therefore, more new bone 
accrual and more longitudinal growth.
While serum P1NP levels were higher in patients with sclerosteosis compared with 
disease carriers, CTX levels, in non-fasting blood samples taken at the same time 
of the day, did not differ between these two groups. In a previous report another 
biochemical marker of bone resorption, hydroxyproline, was found to be within the 
normal range in 3 patients with sclerosteosis (35). These findings are in line with the 
histomorphometric  results of the present study as well as with those in a murine 
model of the disease (36).  In the latter, bone resorption as assessed biochemically 
and histologically, did not differ from that of wild type mice. Wnt signaling in 
osteoblasts decreases bone resorption by downregulating the expression of RANKL 
and upregulating that of OPG (37-39). In addition to stimulating bone formation, 
the lack of sclerostin leading to stimulation of Wnt signaling may, thus, also decrease 
the rate of bone resorption. This premise is supported by the changes in serum P1NP 
and CTX in animals and humans treated with an antibody to sclerostin (27,29).
The results of our study provide further strong evidence for the paradigm that 
inhibition of sclerostin activity has an anabolic effect on bone. Although patients 
with sclerosteosis and disease carriers form a proper model to study the effect of 
decreased sclerostin activity on bone in humans, this model differs from treatment 
with an inhibitor of sclerostin as in these individuals the decreased or absent sclerostin 
production is continuous and permanent while treatment with an inhibitor results 
in an immediate but reversible inhibition of sclerostin. The negative relationship 
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between serum P1NP and age we found in patients and disease carriers suggests that 
in sclerosteosis bone formation is not elevated to the same extent throughout life 
and that the absence of sclerostin alone does not act as a constant stimulus for bone 
formation. This raises the question whether prolonged treatment with a sclerostin 
inhibitor will be associated with a sustained anabolic effect on bone or whether the 
beneficial effect on bone formation may become blunted after a certain period of time. 
It should be noted that sclerostin does not stimulate osteoblastogenesis but rather 
acts at later stages of osteoblast development and inhibits their activity and reduces 
their life-span (5,32,40). In the young, osteoblastogenesis is increased as required for 
skeletal growth whereas it decreases after skeletal maturity. It may, therefore, be that 
in the presence of an increased pool of osteoblasts, as occurs in the young, the lack of 
sclerostin leads to excessive bone formation which, however, decreases considerably 
when this pool is reduced, as occurs in adults.  The potential contribution to these 
responses of other inhibitors of the Wnt signalling pathway, such as Dkk1, warrants 
further investigation. This hypothesis can explain the changes of bone formation 
with age in the studied individuals and suggests that the response to exogenously 
administered inhibitors of sclerostin may be more complex than that illustrated by 
short-term studies in animals and humans. 
In conclusion, our findings provide compelling in vivo evidence of how the absence 
or decreased synthesis of sclerostin leads to increased bone formation in humans. 
Furthermore, inhibition of sclerostin can be titrated since the decreased sclerostin 
levels in disease carriers, did not elevate bone formation to the same extent as in 
patients with sclerosteosis and did not lead to any of the symptoms or complications 
of the disease but had a positive effect on bone mass. Further studies are needed to 
clarify the role of sclerostin on bone resorption.
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Abstract 
Van Buchem disease (VBD) is a rare bone sclerosing dysplasia caused by the lack 
of a regulatory element of the SOST gene, which encodes for sclerostin. We studied 
the demographic, clinical, biochemical and densitometric features of 15 patients with 
VBD (12 adults and 3 children) and 28 related carriers of the gene mutation. 
The clinical course of the disease appeared to stabilize in adulthood with the majority 
of patients reporting no progression of symptoms or development of complications 
with time. Carriers of the disease had no clinical features or complications of the 
disease. Sclerostin could be detected in the serum in all but one patients [mean 8.0 
pg/ml;95% Confidence Intervals (CI) 4.9-11.0 pg/ml], and were lower than those 
of carriers (mean 28.7pg/ml;95%CI 24.5-32.9pg/ml, p<0.001) and healthy controls 
(mean 40.0pg/ml;95%CI34.5-41.0pg/ml, p<0.001). Serum procollagen type 1 amino-
terminal propeptide (P1NP) levels were also significantly higher in adult patients 
(mean 96.0ng/ml;95%CI 54.6-137.4ng/ml vs 47.8;95%CI 39.4-56.2ng/ml, p=0.003 in 
carriers and 37.8ng/ml;95%CI 34.5-41.0ng/ml, p=0.028 in healthy controls). Bone 
Mineral Density (BMD) was markedly increased in all patients (mean z-score 8.7 ± 
2.1, and 9.5 ± 1.9 at the femoral neck and spine respectively); BMD of carriers was 
significantly lower than that of patients but varied widely (mean z-scores 0.9 ± 1.0 
and 1.3 ± 1.5 at the femoral neck and spine, respectively). Serum sclerostin levels 
were inversely correlated with serum P1NP levels (r=-0.39, p=0.018) and BMD 
values (femoral neck r=-0.69, p<0.001; lumbar spine r=-0.78, p<0.001). Our results 
show that there is a gene-dose effect of the VBD deletion on circulating sclerostin and 
provide further in vivo evidence of the role of sclerostin in bone formation in humans. 
The small amounts of sclerostin produced by patients with VBD may explain their 
milder phenotype compared to that of patients with sclerosteosis, in whom serum 




Van Buchem disease (VBD) or “hyperostosis corticalis generalisata familiaris” is 
a rare, autosomal recessive, bone sclerosing dysplasia, first described in 1955 (1). 
Another 13 cases were subsequently identified, all amongst inhabitants of a small 
village of the Netherlands (2, 3). The phenotype of patients with VBD is very similar 
to that of patients with sclerosteosis, a bone sclerosing dysplasia found mainly among 
the Afrikaners in South Africa (4). Both diseases are due to defects of the SOST gene, 
which is located on chromosome 17q12-q21 and encodes sclerostin, an osteocyte-
produced negative regulator of bone formation (5). Whereas sclerosteosis is caused 
by homozygous mutations in the SOST gene, VBD is due to a homozygous deletion 
of a 52 kb regulatory element 35 kb downstream of the SOST gene, which leads to 
impaired production of sclerostin (6-9).   
The clinical and biochemical features of patients with sclerosteosis and healthy 
disease carriers of this genetic abnormality have been well characterized (4, 10, 11), 
but less is known about VBD and carriers of the disease. Available data suggest 
clinical differences between the two sclerosing disorders (12) although information 
is lacking about potential biochemical differences between the two diseases and 
possible relationships between biochemical parameters and clinical and radiographic 
disease characteristics. The purpose of the present study was to characterize the 
demographic, clinical, biochemical and densitometric features of patients with VBD 
and of related carriers of the gene mutation, and to study the relationship between 
circulating sclerostin and bone turnover markers levels and BMD. A further aim 
of the study was to obtain insight in the natural course of VBD by retrospectively 
studying the clinical course of known patients with this disorder.
Subjects and Methods
Subjects
All known adult patients with VBD living in the Netherlands and their first degree 
relatives were invited to participate in this study. The majority of subjects were seen 
at their place of residence while those residing in other parts of the country were 




A complete medical history was obtained from all patients, with special emphasis 
on complaints potentially associated with VBD.  Physical examination including 
detailed neurologic examination and fundoscopy was performed in all patients but 
only when indicated in their relatives.  Z-scores for height and head circumference were 
calculated and compared to the Dutch 1997 height for age-, and head circumference 
for age surveys using Growth Analyzer 3.5 (Dutch Growth Foundation, Rotterdam, 
the Netherlands). 
Non-fasting blood samples were obtained from all subjects for DNA analysis and 
for the measurement of biochemical parameters of calcium and bone metabolism 
and of sclerostin. Subjects were seen at different times of the day, but patients 
and their relatives were seen at the same time on a particular day.  Bone mineral 
density (BMD) of the spine and of the hip were measured by DXA (Lunar Prodigy, 
GE Healthcare, Hoevelaken, The Netherlands). Audiometry results and data from 
previous radiologic examinations were obtained from hospital records. 
The study was approved by the Ethics Committee of the Leiden University Medical 
Center and written informed consent was obtained from all adult participants and 
from parents of children included in the study. 
DNA analysis
DNA was tested for the presence of a homozygous or heterozygous 52kb deletion 
35 kb downstream of the SOST gene on chromosome 17q12-q21, known to be the 
underlying genetic defect for VBD, in patients and carriers.
Serum Biochemistry
Blood was collected from all patients and heterozygous carriers and measured for 
serum calcium adjusted for albumin binding, phosphate, and creatinine, using 
semi-automated techniques. Alkaline phosphatase (ALP) was measured by a fully 
automated P800 modulator system (Roche BV, Woerden, The Netherlands). PTH 
was measured using the Immulite 2500 assay (Siemens diagnostics, Breda, The 
Netherlands). P1NP and β-CTX were determined by the E-170 system (Roche 
BV, Woerden, The Netherlands). 25-hydroxyvitamin D (25-OHD) was measured by 





 Sclerostin was measured in serum with an electrochemiluminescence assay (MSD® 
96-well MULTI-ARRAY® Human Sclerostin Assay, Meso-Scale Discoveries, 
Gaithersburg, Maryland, USA) as previously described (11). Using this assay, we have 
previously shown that sclerostin was undetectable in the serum of all of 19 patients 
with sclerosteosis tested (11). The intra- and inter–assay coefficient of variation were 
6% and 10%, respectively, and  the detection limit was ±1 pg/ml. For comparison 
of sclerostin and P1NP levels we used as control a group of 77 healthy subjects, as 
reported in a previous study (13). Mean age of the control group was 50.3 years 
(range 20-77), and mean BMI was 25,2 kg/m2 (range 19.0-36.5).
Statistical analysis
Statistical analysis was performed using the SPSS 17.0 software.  Differences between 
groups were analyzed using ANOVA or Student’s t-test as appropriate. A Games-
Howell post-hoc test was used, because of inequality in sample sizes. Correlations 
between sclerostin, biochemical markers, age, and BMD values were assessed by 
Pearson’s correlation testing. P1NP and CTX data were log transformed because of 




I. Patients with VBD
Fifteen of the 18 known Dutch patients with VBD consented to participate in the 
study (12 adults and 3 children). The diagnosis was confirmed in all 15 patients by 
the presence of the VBD deletion on chromosome 17q12-q21. Of the 32 first degree 
relatives who participated in the study, 28 adults were found to be carriers of the 
disease and were included in the analysis. Demographic characteristics of patients 
and heterozygous carriers are shown in Table 1.
Clinical features
All 15 patients had experienced in the past one or more episodes of facial palsy. The 
median age at first occurrence was 2.5 years. Facial palsy was already present at 
birth in two patients, and was observed within the first year of life in another two. 
Unilateral or bilateral surgical decompression of the facial nerve was performed in 6 
of the 15 patients. Five of the 15 patients reported recurrent episodes of ipsilateral 
facial palsy. Fourteen patients reported some degree of hearing impairment. In 6 of 
these, this preceded or occurred concurrently with a middle ear infection. The age at 
which hearing loss became noticeable differed markedly among patients, developing 
in early childhood in some, while only noticed in late adulthood in others. Five of the 
15 patients used hearing aids and 6 had undergone previous surgery (mastoidectomy 
because of chronic otitis media, removal of exostosis from the auditory canal, placement 
of Bone Anchored Hearings Aids (BAHA)).No patient reported visual impairment. 
Two patients reported a decreased sense of smell.  Three patients had previously 
experienced symptoms of raised intracranial pressure,.   Following lumbar punction, 
symptoms completely resolved in one patient, while in another they improved over 
several months with concomitant treatment with acetazolamide. In the third patient 
a ventricular peritoneal drain had to be placed and treatment with prednisone was 
given leading to complete resolution of symptoms (14). One patient had sustained a 
fracture of the wrist on two separate occasions, one at the age of 14 years after falling 
from a tree, and the other at the age of 17 years after a motorcycle accident. No 
fractures were reported by any other patient, despite involvement of some in major 
accidents. All patients reported to have trouble keeping afloat in water, only able to 
keep from sinking by active and continuous swimming. 
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The clinical course of the disease appeared to stabilize in adulthood with the majority 
of patients reporting no progression of symptoms or development of complications 
with time. Three patients (aged 49, 52 and 82) did, however, experience a further 
decrease in hearing with time. and one patient (age 43) reported continuing increase 
in the size of her lower jaw . None of the patients reported symptoms related to other 
organs such as heart, lungs, urogenital or gastrointestinal tracts, except for an 82 year 
old man,  who had diabetes mellitus and heart failure associated with hypertension.
Table 1. Van Buchem disease: characteristics of patients and carriers of the disease
Values are given as mean ± SD; a patients vs carriers; FN=Femoral Neck
Van Buchem disease
Patients Carriers p-valuea
Male: female 10:5 17:11 0.11
Age (years) 39.07 ±20.9 36.0±16.9 0.68
Height (cm) 182.9 ± 9.5 175.2 ± 8.2 0.02
Height (z-score) 0.31 ±0.81 -0.16 ± 0.88 0.12
BMI (kg/m²) 27.1 ± 4.2 25.0 ± 5.8 0.33
BMD FN (g/cm²) 2.16 ± 0.41 1.17 ± 0.16 <0.01
BMD FN z-score (sd) 8.7 ± 2.1 0.9 ± 1.0 <0.01
BMD spine (g/cm²) 2.13 ± 0.54 1.31 ± 0.17 <0.01
BMD spine z- score (sd) 9.5 ± 1.9 1.3 ± 1.5 <0.01
PTH (pmol/l) 8.8 ± 5.9 5.7 ± 4.0 0.13
Calcium (mmol/l) 2.42 ± 0.22 2.45 ± 0.15 0.62
Phosphate (mmol/l) 1.12 ± 0.33 1.10 ± 0.22 0.96
25 OH D (nmol/l) 53.9 ± 20.3 58.4 ± 14.7 0.43
Creatinine (μmol/l) 77.5 ± 40.0 70.9 ± 12.1 0.53
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Clinical Examination 
On clinical examination all patients had normal stature (Table 1) and all adults had 
some degree of facial distortion. Eleven of the 12 adult patients had a large, high 
forehead, and the mandible was enlarged in 10, with one patient having had corrective 
surgery of her lower jaw. The 3 children had no apparent facial dysmorphic features 
(15). The average circumference of the skull in adults was 63.6 cm (z-score:+3.4) for 
men,  and 61.3 cm (z-score: +3.2) for women. In the children skull circumferences 
were 50.5 cm (z-score: 0), 49.8 cm (z-score: 0), and 52.3 cm (z-score: +1.3). 
None of the patients had any abnormalities of hands or digits, such as syndactyly or 
nail hypoplasia. Blood pressure was normal in all but one patient and all had normal 
sinus cardiac rhythm.
On neurological examination none of the patients had anosmia, visual field defects 
or papilloedema, except for a boy aged 5 years. Oculomotor function was normal 
and pupil responses were adequate in all. Sensibility of the face was impaired in two 
patients. All patients had slight to severe facial palsy (House Brackman score II to V) 
which was unilateral in two and bilateral in the remaining 13 patients. On previous 
otoscopy, exostosis was observed in the bony part of the external auditory canal in 
10 patients, in some of whom the external auditory canal was narrowed to a lumen 
of less than 2 mm. In one patient there was a complete fixation of all the ossicles 
of the middle ear. Hearing tests had been performed at some stage in all patients. 
In 3 patients there was no hearing loss, while this was mild in 3, moderate in 3, 
moderately severe in 2, severe in 1 and profound in 3. The type of hearing loss varied 
between patients, (sensorineural, conductive or mixed). Deep tendon  reflexes were 
normal and all patients had normal plantar responses. 
Bone Mineral Density
Bone mineral density (BMD) measured in 11 adult patients, and in 2 children, was 
increased in all (Table 1).  BMD increased with age, but appeared to reach a plateau 




CT scans of the mastoid, skull, and/or cervical spine had been performed in 9 
patients. All scans showed a generalized increased thickness of all skull bones, with 
calvarial width measurements of greater than 2 cm in adult patients. A CT scan of 
the mastoid bones has been performed in 7 adult patients, in all of whom there was 
an evident narrowing or the internal auditory meatus. Narrowing of the internal 
auditory meatus could already be observed in a 3-year old, but absent in a 6-year 
old child. Narrowing of the facial nerve canal was observed in 3 patients. A cervical 
spinal stenosis due to hyperostosis of the vertebrae and to degenerative changes of 
the intervertebral discs was observed in 3 patients, in one of whom it resulted in 
a myelopathy. One patients had lumbar spine stenosis due to hypertrophic facet 
arthrosis and bulging of the intervertebral discs. 
II. VBD disease carriers
Two of 28 studied heterozygous carriers had complaints potentially related to VBD. 
These 2 carriers, the mother and sister of a studied patient, had both sustained a 
transient unilateral facial palsy during labor which was quickly resolved.  At the time 
of the study there were no residual neurological signs of facial paralysis in either. Six 
of the 28 carriers had sustained a fracture  (upper arm 2,  leg 2 , wrist 1, metacarpal 
Figure 1. Bone mineral density (Z-scores) of the lumbar spine (left panel) and femoral neck 
(right panel) in patients with van Buchem disease (closed circles) and heterozygous carriers of the 
disease (open circles). Dotted lines represent -2, 0 and +2 standard deviations. 
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1), all, but one, having occurred in childhood, and all associated with appropriate 
trauma.
Physical examination of the 28 carriers was unremarkable. Height and BMI were 
normal and not significantly different from those of patients (Table 1). All subjects 
had normal blood pressure and sinus cardiac rhythm. 
Mean BMD at the lumbar spine and the femoral neck are shown in Table 1. BMD 
values were significantly lower than those of patients but varied widely (Figure 1). 
z-scores ranged between -2.2 and +4.6 at the spine, and between  -1.1 and + 2.9 at 
the femoral neck At the spine,  19 subjects (70%) had BMD z- scores above 0 with 
6 subjects (22%) exceeding 2 SDs.  BMD z-scores of the femoral neck were greater 
than 0 in 21 carriers (81%), exceeding 2 SDs in 3 subjects (12%). 
Laboratory investigations
Blood was collected from 14 patients and 28 carriers and from 77 healthy controls 
for measurement of biochemical markers of calcium metabolism and bone turnover. 
Mean calcium, phosphate, 25-OHD, and PTH concentrations did not differ between 
patients and carriers (Table 1). There were no abnormalities in hematological 
parameters in the 7 patients in whom these were tested.
Serum P1NP levels declined with age in both patients and carriers (Figure 2). In adult 
patients, this was greater than 65 ng/ml in 67%. Serum P1NP was also increased in 
19% of adult heterozygous carriers. Serum P1NP levels were significantly higher in 
adult patients with VBD than in carriers of the disease (96.0; 95%CI 54.6-137.4 ng/
ml vs 47.8; 95%CI 39.4-56.2 ng/ml, p=0.003) and healthy controls (37.8; 95%CI 34.5-
41.0, p=0.028) (Figure 3). There was no significant difference in serum P1NP values 
between carriers and healthy controls (p=0.14). 
Serum levels of CTX, obtained in the non-fasting state, declined with age in patients, 
but not in carriers (Figure 2). These were higher than the upper limit of the normal 
reference range in 3 patients (25%) but in none of the carriers. Serum CTX levels 
were higher in patients (mean 447 pg/ml; 95%CI 266-628 ng/ml) compared to carriers 
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(mean 216 pg.ml; 95%CI 167-266 pg/ml) (p=0.020). Serum levels of CTX and P1NP 
were significantly correlated in both patients (r=0.95, p<0.001) and carriers (r=0.71, 
p<0.001).
Serum sclerostin
Sclerostin was detectable in the serum of all but one patient, and ranged between 
1.7 pg/ml and 16.9 pg/ml. All carriers had detectable serum sclerostin levels with 
values ranging between 14.4 pg/ml and 55.0 pg/ml. VBD patients had significantly 
lower sclerostin levels (mean 8.0 pg/ml; 95%CI 4.9-11.0 pg/ml) compared to carriers 
(mean 28.7 pg/ml; 95%CI 24.5-32.9 pg/ml, p<0.001), and to healthy controls (mean 
40.0 pg/ml; 95%CI 34.5-41.0 pg/ml, p<0.001). Mean sclerostin levels were also 
significantly lower in carriers than in controls (p<0.001) (Figure 3).
The relationship between serum sclerostin, bone turnover markers and BMD was 
studied by pooling data from all adult patients and carriers, in order to obtain a 
broader range of sclerostin values. In this pooled cohort, serum sclerostin levels were 
inversely correlated with serum P1NP levels (r=-0.39, p=0.018) (figure 4 A), but 
not with serum CTX (r=-0.28, p=0.11). Serum sclerostin levels were also inversely 
Figure 2. Relationship between serum P1NP levels and age (left panel) and CTX levels and age 
(right panel) in patients with van Buchem disease (closed circles) and heterozygous carriers of the 
disease (open circles). Dotted lines represent the upper limit of the normal adult reference range 




correlated with BMD (g/cm2) at both the femur neck (r=-0.69, p<0.001) and the 
lumbar spine (r=-0.78, p<0.001). 
Figure 3. Serum P1NP (left panel) and sclerostin (right panel) levels in healthy controls, adult 
patients with van Buchem disease and heterozygous carriers of the disease. Bars represent SEM. 
a: p<0.001; b: p=0.003; c: p=0.028; d: p=0.13
Figure 4. Relationship between serum P1NP and sclerostin levels in patients with van Buchem 




Since the first description of VBD, approximately 30 cases have been reported, of 
which the vast majority is Dutch and living in the Netherlands. Before the discovery 
of the genetic background of the disease, a number of patients from the USA (16, 17), 
UK (18-20), and Italy (21) were diagnosed as having VBD, based on their clinical 
presentation. In some of these cases, however, there was an autosomal dominant 
inheritance (17, 19, 21), making it more likely that they suffered from a ‘high bone 
mass disorder’, or Worth’s disease (22), caused by mutations in the LRP5 receptor 
as later confirmed by genetic analysis in an Italian family (23). However, two siblings 
with genetically confirmed VBD were recently reported from Germany, although no 
information about their genetic background were provided (24). 
The phenotype of our patients with VBD is in keeping with previously described 
clinical features of the disease (1-3, 15, 22, 27). Our data also confirm that the 
clinical  course of VBD is less severe than that of sclerosteosis, in which the majority 
of patients develop conductive hearing loss in early childhood and raised intracranial 
pressure around adolescence or early adulthood (4, 11), the latter being the main 
cause of death in patients with sclerosteosis.  Raised intracranial pressure was much 
less frequently observed in patients with VBD (20%), and none of the 3 patients with 
documented increased intracranial pressure required a craniotomy, in contrast to 
the case in patients with sclerosteosis (25).  There was, however, a large variation in 
the severity of clinical findings among patients but none of the measured laboratory 
parameters could explain these differences.
Facial palsy was a universal finding in studied patients. It developed early, at an 
age similar to that of patients with sclerosteosis, and was already present at birth 
in two of them. The reported occurrence of facial palsy at birth in a number of 
patients with VBD suggests that the fallopian canal may already be narrowed in 
utero. However, the regulatory element of SOST, which is lacking in patients with 
VBD, was not found to control embryonic SOST transcription (26), which might 
explain the absence of syndactyly and other digit abnormalities in VBD. Hearing loss 
was also common but less severe than in patients with sclerosteosis.  These findings 
suggest that the extent of bone overgrowth during the first years of life might be 
similar in VBD and in sclerosteosis and progression later in life appears to occur more 
slowly in VBD than in sclerosteosis.  Complications associated with bone overgrowth 
Van Buchem disease
82
appeared to stabilize after the third decade of life in both diseases (4, 11).
Consistent with the clinical findings and similar to the case in sclerosteosis (11), 
serum P1NP levels declined with age, reaching normal levels in several patients. 
This was consistent with no further increases in BMD. The stabilization of BMD we 
observed, contrasts with the findings of a previous study, in which the diaphyseal / 
metaphyseal ratio and the cortical thickness of metacarpals were reported to increase 
with age in patients with VBD, and in which an adult patient with progressive growth 
of the mandible was described (27). The oldest patient in our study, aged 82 years, 
had an enlarged mandible that demonstrated no progressive growth for decades, 
and progressive enlargement of the mandible has not been reported in patients with 
sclerosteosis. 
VBD is caused by a deficiency of sclerostin synthesis. As shown here, all but one 
of the patients had detectable levels of sclerostin in serum which were, however, 
significantly lower than those of heterozygous carriers of the disease.  These data 
contrast with findings in patients with sclerosteosis (11) in whom the SOST gene is 
affected, rendering the synthesis of sclerostin impossible. The regulatory element which 
is missing in VBD has been shown to be of crucial importance for the transcription 
of SOST in bone (26). It is, therefore, likely that in VBD, sclerostin production is 
due either to leaky transcription, the accidental transcription of a gene without prior 
activation of its regulatory element, or to the production of sclerostin by cells other 
than osteocytes in which this regulatory element is not essential. In favour of the 
first hypothesis is the finding of a weak sclerostin signal by immunological staining 
in a bone biopsy from a patient with VBD (28)Alternatively, circulating sclerostin 
might be secreted by cementocytes or hypertrophic chondrocytes (28, 29). We have 
previously shown that sclerostin is not expressed in cementocytes of patients with 
VBD (28) but there are no data about its potential production by chondrocytes in 
these patients. In contrast to patients with sclerosteosis who are tall, patients with 
VBD have normal height which is not different from that of carriers of the disease. 
We have previously speculated that the tall stature of patients with sclerosteosis 
might be due to lack of sclerostin at the growth plate which might not be the case 
in patients with VBD and at least part of the measured circulating sclerostin may 
originate from chondrocytes. Clearly more studies are needed to clarify this issue. 
Independently of these considerations, the milder clinical phenotype of patients with 
VBD compared to that of sclerosteosis is in line with the differences in sclerostin 
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levels between the two diseases. 
As with sclerosteosis, a gene-dose effect was also present in VBD with patients having 
lower levels of sclerostin and higher levels of P1NP than their heterozygous carriers. 
These sclerostin levels were further significantly and negatively associated with BMD 
underscoring the importance of sclerostin in the process of bone formation.  In line 
with the findings in patients, carriers of VBD had higher levels of serum sclerostin 
than carriers of sclerosteosis.  Consequently, the difference in mean serum P1NP 
levels between VBD carriers and healthy controls was also smaller, and did not 
reach significance.  There was also a large variation in BMD values in carriers with 
some individuals having very high values while others had low values, in contrast 
to the BMD of carriers of sclerosteosis which was found to be either high normal or 
increased, with none of the patients having low values (30).
Since its discovery a decade ago there has been much interest in sclerostin because 
of its key role in the regulation of bone formation and its use as target for new 
bone building therapies for osteoporosis (31). Our data provide further support to 
the rationale that sclerostin functions as a negative regulator of bone formation 
in humans. Not only had patients with VBD higher P1NP levels in comparison to 
carriers and controls, but sclerostin levels were also negatively associated with P1NP 
levels in a pooled cohort of patients and carriers. 
The stabilization of the clinical course of VBD with time, and the decline in P1NP 
levels in patients with VBD and sclerosteosis with time raise the question whether 
sclerostin controls bone formation to the same extent throughout life. During 
childhood, longitudinal growth and strengthening of the skeleton by bone modelling 
requires high bone formation rates. We believe that sclerostin is extremely important 
during bone modelling to keep the vast numbers of active osteoblasts in check. Later 
in life, when the skeleton has matured, bone formation takes place as part of the 
bone remodeling process, and osteoblast number and activity is far less than that 
required for the process of bone modeling. Although sclerostin plays a clear role in 
the regulation of osteoblast activity during bone remodeling, sclerostin deficiency 
appears to be less important during this process than during bone modeling. It 
may, thus, well be that the absence of sclerostin during bone remodeling may be 
compensated to a certain extent by the action of other Wnt-antagonists, such as 
DKK1, or by other mechanisms maintaining the equilibrium between bone formation 
and resorption. This remains however speculative, and further studies are required to 
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examine this hypothesis. 
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Abstract
A 25 year old man with the rare sclerosing bone disorder van Buchem disease 
presented with progressively worsening headaches eventually becoming persistent 
and associated with papilloedema. Increased intracranial pressure was diagnosed 
and the patient had a ventriculo-peritoneal drain inserted as well as simultaneously 
receiving treatment with prednisone. Before starting treatment, there was biochemical 
evidence for increased bone turnover and for steady increases in BMD at spine and 
total hip, despite the patient having reached his peak height of 197 cm at the age 
of 19 years. Treatment with prednisone resulted in biochemical and histological 
suppression of bone formation as well as of bone resorption, and in arrest of further 
bone accumulation.
Our data suggest that glucocorticoids (GC) may represent an attractive alternative to 
the high risk surgical approaches used in the management of patients with progressive 
sclerosing bone disorders. Our findings also suggest that whereas sclerostin may not 
be required for the action of GC on bone formation, it may well be important for the 
action of GC on bone resorption. The exact mechanism by which sclerostin may be 




Van Buchem disease is a rare bone sclerosing disorder described for the first time in 
1955.(1) It belongs to the group of craniotubular hyperostoses and is characterized 
by progressive generalized osteosclerosis, particularly of the mandible and the skull, 
due to excessive bone formation.(2) It is caused by a 52kb deletion 35kb downstream 
the SOST gene which encodes sclerostin on chromosome 17q12-21.(3,4) This protein 
is produced in the skeleton exclusively by the osteocytes and inhibits bone formation 
by antagonizing the Wnt signaling pathway.(5) Clinical manifestations of the 
disease are due to entrapment of cranial nerves often associated with facial palsy, 
and loss of hearing and smell.(2) Van Buchem disease is thought to have milder 
clinical manifestations than sclerosteosis, a craniotubular hyperostosis with similar 
phenotype due to inactivating mutations of the SOST gene.(6,7) Management of the 
complications of both these sclerosing dysplasias is surgical, aiming at removal of the 
excess of bone, a technically difficult and sometimes dangerous procedure.(8,9,10) 
No medical treatment is available for either sclerosing diseases. Glucocorticoids are 
known inhibitors of bone formation(11,12) and we hypothesized that administration 
of these agents to patients with complications due to bone overgrowth may arrest its 
further progress.
We present here sequential observations of a patient with van Buchem disease with 
life-threatening increased intracranial pressure who was successfully treated with 
prednisone.   
Case Report
The patient first came under our care at the age of 10 years with an established 
diagnosis of van Buchem disease. The disease was clinically and radiologically 
diagnosed in infancy and later genetically confirmed by the finding of a 52kb 
homozygous deletion 35 kb downstream the SOST gene on chromosome 17q12-q21 
[the patient was briefly described (patient 15) by Staeling-Hampton et al(3)]. The 
parents are consanguinous and were both confirmed to be heterozygotes for the 
disease. There were 3 phenotypically normal sisters in whom no genetic testing has 
been so far undertaken.
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As described in this disorder, clinical manifestations started early in childhood. The 
patient had a facial palsy at the age of 3 years and developed progressive deafness 
requiring the use of a hearing aid by the age of 10 years, followed by bilateral Bone 
Anchored Hearing Aids. He has been otherwise well with normal growth development 
along the 95th centile reaching a final height of 197 cm by the age 19 years. He 
completed his secondary education and is employed  as office assistant manager. He 
married at the age of 20 years and he is father to 3 healthy children. 
He demonstrated the typical clinical and radiological features of van Buchem disease, 
with enlarged head and mandible and no syndactyly or other digit malformations. 
During the 15-year duration of follow-up there were no other clinical signs or symptoms 
and blood pressure was normal. Haematological and biochemical parameters, 
including these of mineral metabolism demonstrated no abnormalities over the years. 
Skeletal radiographs showed thickening of the calvarium, base of the skull and long 
bones and sclerosis of the vertebrae (Figure 1). Bone Mineral Density (BMD) of the 
spine and hip were markedly increased at presentation (Z-score +6.2) and continued 
to increase in parallel with that of his healthy peers without, however, attaining a 
peak (highest z-score being 7.7). Biochemical markers of bone turnover were always 
increased compared to normal values for age, but followed a normal pattern of change 
with a further increase during the growth spurt and a progressive decline thereafter, 
although never reaching the normal range (Figure 2). 
At the age of 23 years the patient complained of progressive headaches, eventually 
becoming persistent, associated with dizziness and by worse signs of increased 
intracranial pressure, in the form of papilloedema. The diagnosis was confirmed 
radiologically and a ventricular-peritoneal drain was implanted and he was 
concomitantly started on prednisone 30 mg/d which was reduced to 10 mg /d within 
one month. In the following 2 years he received different doses of prednisone, as 
depicted in Figure 3. These interventions were followed by rapid improvement of his 
symptoms which was sustained during the follow-up period.
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Figure 1: Radiographs of the skull, showing thickening of the calvarium and the base of the skull, 
and of the hand illustrating the absence of syndactyly or other malformations.
Figure 2. Sequential measurement of serum Alkaline Phosphate (AP) in U/l, urinary 
hydroxyproline to creatinine tario (OHP/Cr) in μmol/mmol and height (cm) in a patient with 
van Buchem disease  over a 10-year period. Interrupted lines indicate the upper limit of the 
normal range.
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Methods
The biochemical markers of bone turnover P1NP and β-CTX were measured in serum 
at regular intervals using the E-170 system (Roche BV, Woerden, Holland). BMD 
was measured by DXA (Hologic QDR 4500, Waltham, MA, USA). An iliac crest 
biopsy was obtained after in vivo labeling with two courses of tetracycline separated 
by 12 days. Bone histomorphometry was performed on undecalcified histological bone 
sections by Dr Pascale Chavassieux, INSERM Unit 831, University of Lyon, Faculty 
of Medicine R Laennec, France). Immunohistochemical staining for sclerostin was 
performed in our laboratory using a previously described technique.(13)
Results
Biochemical markers of bone turnover
The changes in serum P1NP and β-CTX before and during prednisone treatment are 
depicted in Figure 3. Before treatment, values of both markers of bone turnover were 
elevated and decreased to within the normal reference adult range within 4 weeks of 
starting treatment with prednisone. The effect of prednisone on bone turnover was 
dependent on the dose administered and attempts to reduce the dose below 5 mg/d 
were associated with increases in serum markers of bone turnover. It was notable that 
during treatment there was a close relationship between serum β-CTX and P1NP 
values, with the two markers demonstrating parallel changes during adjustments 
of the dose of prednisone, suggesting a tight coupling of bone resorption and bone 
formation. There was a highly significant correlation between the two markers 
throughout the 2-year period of follow up (R2=0.765).
BMD
The changes in BMD measured at the spine and at the hip for the 6 years preceding 
the start of prednisone treatment and for 2 years thereafter are shown in Table 1. 
Despite high baseline values, BMD continued to increase steadily during adulthood 
by about 4% per two years, demonstrating no further increase after two years of 




On an iliac crest biopsy, taken two years after the start of prednisone treatment, there 
was sclerosis and no evidence of active bone remodeling. Cancellous bone volume was 
clearly increased and bone trabeculae were thick and well connected. The extent 
of eroded surfaces was very low (0.4%; normal 3.1±1.1%) and Howship’s lacunae 
were devoid of osteoclasts. In addition, no osteoid seams were seen and there was 
no tetracycline uptake upon examination under fluorescent light. As expected and 
previously described,(14) osteocytes did not stain for sclerostin.
Figure 3. Biochemical markers of bone formation and resorption before and during treatment 
with prednisone. P1NP: diamonds and solid line; β-CTX: closed circles and interrupted line.
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Discussion
This case illustrates the beneficial effect of prednisone treatment on bone metabolism 
in a patient with van Buchem disease and life-threatening increased intracranial 
pressure. Treatment resulted in a histologically documented dramatic decrease in 
bone formation. Following therapy there was also no further increase in BMD at the 
spine and the hip. Although clinical manifestations of increased intracranial pressure 
improved significantly, this cannot be solely attributed to treatment with prednisone, 
as the patient had a ventriculo-peritoneal drain simultaneously implanted at the time 
of starting prednisone. 
Before prednisone treatment, the patient had an increased rate of bone  turnover, as 
assessed biochemically, associated with a continuous increase in BMD of the spine 
and at the hip. The biochemical markers of bone formation P1NP and osteocalcin 
have been previously reported to be elevated in 6 patients with van Buchem disease 
compared to their levels in disease carriers, being above the upper limit of the normal 
range in 3 of them.(15) Urinary NTX levels were higher in 4 patients with the disease 
compared to carriers. Bone density measured in the phalanges by radiographic 
absorptiometry was elevated in all these patients.(15) There are however to date 
no longitudinal data reported in patients with van Buchem disease. In our patient, 













2-2001 193.9 1.634 - 1.410 -
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at least up to the age of 23 years, both biochemical markers of resorption and 
formation were increased. The clinical progression of the disease, which was due to 
bone overgrowth, as also evidenced by the steady  increase in BMD, prompted us to 
use glucocorticoids in an attempt to arrest the process of bone accumulation. 
The beneficial use of glucocorticoids has been previously reported in a patient with 
craniotubular hyperostosis due to an unidentified genetic defect. (16)  In this patient, 
prednisone given for three courses of 10 weeks each, reduced serum osteocalcin but 
had no effect on urinary deoxypyridinoline and there were no reported changes 
in BMD. In a few cases with progressive diaphyseal dysplasia, a craniotubular 
hyperostotic disorder distinct from van Buchem disease, which is due to mutations 
of the gene encoding TGFβ, prednisone treatment during childhood and adolescence 
led to clinical(17,18) and in one case radiological improvement.(19)
Glucocorticoids have a deleterious effect on the skeleton, increasing bone fragility by 
systemic and local actions.(11) Their main action on bone metabolism is to decrease 
bone formation by inhibiting of the proliferation and differentiation of osteoblasts 
and increasing their rate of apoptosis.(12,20) Glucocorticoids have also been reported 
to increase bone resorption, particularly during the early phase of treatment, by 
stimulating osteoclastic activity and survival through an effect on the RANKL/OPG 
signaling pathway.(21-23) Consistent with these findings, studies in animals(24) and 
in humans(25-33) have shown that administration of glucocorticoids significantly 
reduce biochemical markers of bone formation, but have no effect or even increase 
those of bone resorption. Remarkably, administration of prednisone to our patient did 
not only decrease bone formation, but also bone resorption within 4 weeks of starting 
of treatment. Serum P1NP and β-CTX decreased and increased concurrently during 
alterations of prednisone dose, suggesting a tight coupling of bone resorption and 
formation during treatment. This was further supported by the strong correlation 
between the two biochemical markers of bone turnover before and during prednisone 
treatment. 
The reason for this unique response of bone resorption to prednisone is not apparently 
clear but may well be related to the genetic defect of our patient with van Buchem 
disease.  Recent studies have indicated that at least some of the negative effects of 
glucocorticoids on osteoblast function are due to inhibition of the canonical Wnt 
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signaling pathway through stimulation of the Wnt antagonists Dkk1, Sfr1 and 
sclerostin and activation of GSK3β.(34-36) In addition, it has been reported that in 
osteoblasts Wnt signalling decreases bone resorption by downregulating the expression 
of RANKL and upregulating that of OPG,(37-40) an action that can be reversed by 
glucocorticoids.(21-23) It may thus be that sclerostin is not required for the action 
of glucocorticoids on bone formation, as suggested by the clear reduction of bone 
formation in our patient in the absence of sclerostin. In contrast, sclerostin may well 
be important for the action of glucocorticoids on bone resorption. We propose that in 
the absence of sclerostin glucocorticoids may lose their ability to stimulate RANKL 
and decrease OPG by a mechanism that is as yet to be explored. In support of this 
hypothesis are the data in above mentioned patient with craniotubular hyperostosis 
treated with prednisone.(16) This patient was phenotypically very similar to ours and 
had increased bone turnover before treatment, although genetic analysis excluded 
abnormalities in the SOST gene. In this patient, prednisone treatment was associated 
with a significant decrease in serum osteocalcin but with no parallel change in urinary 
DPD excretion, a response compatible with that reported in other human studies. 
It may be therefore that sclerostin besides its critical role in the regulation of bone 
formation is also involved in the regulation of bone resorption as has also been 
reported for Dkk1, another inhibitor of the Wnt signaling pathway.(41)
The long-term follow-up of this patient with life-threatening complications as a result 
of excess bone formation, illustrates the beneficial effect of prednisone treatment on 
bone metabolism and suggests that using glucocorticoids may represent an attractive 
medical alternative to the currently used technically difficult and complication 
associated surgical treatments of such patients. The results suggest further that 
sclerostin may be involved in the regulation of bone resorption by a mechanism that 
needs to be further explored.
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Abstract 
Context: Increased bone fragility is a frequent complication of hypercortisolism due 
predominantly to suppression of bone formation. Sclerostin is an osteocyte-produced 
negative regulator of bone formation, which is up-regulated by glucocorticoids in 
mice. 
Objective: To assess the effect of endogenous hypercortisolism on circulating 
sclerostin and bone turnover in humans. 
Design: We measured sclerostin, CTX, P1NP and FGF23 in blood samples of 21 
patients with endogenous hypercortisolism and 21 age- and gender-matched controls. 
In 12 patients measurements were repeated at various time intervals after successful 
surgical treatment (transsphenoidal surgery or adrenalectomy). 
Results:   Plasma sclerostin levels were significantly decreased in patients compared 
to controls (112 ± 49  vs 207 ± 48 pg/ml, p<0.001). In the 12 patients who were 
evaluated after surgical treatment,  sclerostin levels increased from 121.4 ± 46.5 pg/
ml to 175.8 ± 78.5 pg/ml (p=0.003).  These changes in plasma sclerostin levels were 
accompanied by significant increases in levels of FGF23 (from 44.2 ± 12.2 pg/ml to 
84.0 ± 58.8 pg/ml , p=0.017)  and of the bone turnover markers P1NP (from 31.7 
±18.2 ng/ml to 94.2 ± 92.2 ng/ml, p=0.037) and CTX (from 134.2 ± 44 pg/ml to 
409.2 ± 285 pg/ml, p=0.005). 
Conclusions: Contrary to the findings in mice, circulating sclerostin is decreased 
in patients with chronic endogenous hypercortisolism and increases after treatment. 
These findings suggest that in humans chronic exposure to glucocorticoids affects the 




Glucocorticoid excess increases bone loss and fragility leading to glucocorticoid-
induced osteoporosis (1;2). The action of glucocorticoids on bone is complex and 
involves local and systemic factors which adversely affect bone mass and quality. Of 
these, suppression of bone formation and increased rate of apoptosis of osteoblasts 
and osteocytes are considered major determinants of the deleterious effect of 
glucocorticoids on bone 
In osteoblasts, glucocorticoids inhibit Wnt-signaling (3,4), a pathway essential for 
osteoblast proliferation, differentiation and survival, enhance the expression of 
RANKL and reduce that of OPG promoting also osteoclast activity (5,6). In recent 
years the osteocyte-derived protein sclerostin has emerged as a key inhibitor of the 
Wnt signaling pathway in osteoblasts. In rodents, glucocorticoids stimulated the 
expression of SOST, the gene encoding sclerostin (3) and a neutralizing antibody 
against sclerostin prevented glucocorticoid-induced bone loss (7).  These findings 
suggest that glucocorticoids may exert their action on bone formation by stimulating 
the production of sclerostin. In the present study we tested this hypothesis in humans. 
For this, we studied patients with endogenous hypersecretion of cortisol because in 
glucocorticoid-treated patients disease-related factors may have independent effects 
on bone metabolism and fragility and may also affect the synthesis of sclerostin(8,9). 
Patients and Methods
Patients 
We studied 21 consecutive patients with endogenous hypercortisolism. The diagnosis 
and causes of hypercortisolism were established as previously described (10).  Fifteen 
patients had ACTH producing pituitary adenomas, 2 had adrenal adenomas, 4 had 
ectopic ACTH production (unknown origin 2, neuroendocrine endocrine tumor 1 and 
metastatic melanoma 1). Non-fasting blood samples were obtained from all patients 
at different times of the day, mainly in the afternoon. 
In 12 of the 21 patients blood samples were also obtained at various time intervals 
following surgical treatment and achievement of biochemical remission. Eight of these 
patients were treated by transphenoidal surgery and 4 by bilateral adrenalectomy. 
Remission was established by an adequate suppression of plasma cortisol after 1 
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mg dexamethasone overnight and disappearance of clinical signs and symptoms 
of hypercortisolism postoperatively (10).  At the time of blood collection 8 of 
the 12 patients were receiving substitution therapy with hydrocortisone (n=7) or 
dexamethasone (n=1) and 2 patients used L-thyroxine for secondary hypothyroidism. 
Preoperative levels of sclerostin and bone turnover markers were compared to those of 
21 age- and gender-matched healthy volunteers who were recruited by advertisements. 
None of these individuals used any medication or had any illness requiring medical 
attention. Similar to patients, non-fasting blood samples were obtained from controls 
in the afternoon. 
All studied subjects (healthy and patients) had normal renal function and serum 
calcium and phosphate concentrations.
Biochemical measurements
Creatinine was measured by semi-automated techniques. Intact PTH was measured 
by the Immulite 2500 (Siemens diagnostics, Breda, Holland). Aminoterminal 
propeptide of type 1 procollagen (P1NP) and beta C-terminal telopeptide (CTX) were 
determined by the E-170 system (Roche BV, Woerden, the Netherlands). Sclerostin 
was measured by an electrochemiluminescence assay (MSD 96-well MULTI-ARRAY 
Human Sclerostin Assay, Gaithersburg, MD, USA), as previously described (11). 
With this assay no sclerostin could be detected in the serum of 19 patients with 
sclerosteosis, whereas sclerostin was detectable in serum of 77 healthy individuals. 
In previous studies we measured sclerostin in serum while in the present study we 
used EDTA plasma samples due to their availability. Because of earlier reported 
differences in sclerostin levels in plasma and serum (12), we first measured sclerostin 
levels in simultaneously obtained serum and plasma samples from 26 individuals 
with serum sclerostin levels ranging from 16.2 to 94.7 pg/ml. Compared to serum, 
sclerostin levels were on average 3.6-fold higher in plasma but the two values were 
highly and significantly correlated (r=0.91, p=0.001). 
Fibroblast Growth Factor 23 (FGF23) levels, as an independent index of osteocyte 
function, were measured with the Intact FGF23 ELISA kit (Kainos laboratories, 





Values are reported as mean ± standard deviation, unless otherwise stated. 
Differences between patients and controls were assessed by t-test. Of the 12 patients 
who were studied during biochemical remission, differences in sclerostin levels and 
other biochemical markers before and after surgical treatment were analyzed by 
paired t-tests. Correlations between markers and changes in markers were assessed 
by Pearson’s correlation. Normality of distribution was assessed by Shapiro-Wilk 
tests. Levels of CTX and FGF23 were log transformed because of skewness. Data 




Group characteristics and relevant biochemical parameters at baseline in patients and 
controls are shown in table 1. Of the 21 patients with endogenous hypercortisolism 
included in the study, 16 were female (11 premenopausal and 5 postmenopausal) and 
5 were male. Mean age was 41.3 ± 12.7 years, mean weight 86.6 ± 17.1 kg, and mean 
BMI 31.2 ± 6.6 kg/m2. 
Mean plasma sclerostin levels were significantly lower in patients compared to controls 
(112.0 ± 49.0 pg/ml vs 207.2 ± 48.4 pg/ml, p<0.001), while there were no significant 
differences between the two groups in levels of P1NP, CTX or FGF23 (Table 1).
Mean afternoon cortisol concentrations of patients was 0.63 ± 0.31 μmol/l and there 
was no relationship between plasma cortisol and sclerostin levels(r=-0.28, p=0.31), 
or P1NP (r=0.45, p=0.09); however, plasma cortisol concentrations were significantly 
correlated with serum CTX levels (r=0.65, p=0.009). Serum levels of CTX and P1NP 
were also significantly correlated in these patients (r=0.55, p=0.03).
Changes in biochemical parameters after treatment 
Mean plasma cortisol concentration was 0.18 ± 0.18 μmol/l in the 12 patients who 
were followed after surgical treatment. Changes of all studied biochemical parameters 
during remission of the disease are shown in Figure 1. Remission was associated 
with a significant increase in mean sclerostin levels (from 121.4 ± 46.5 pg/ml to 
175.8 ±78.5 pg/ml; p=0.003). Similarly, P1NP levels increased from 31.7 ±18.2 ng/
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ml to 94.2 ± 92.2 ng/ml (p=0.037), and CTX levels increased from 134.2 ± 44 pg/
ml to 409.2 ± 285 pg/ml (p=0.005). Plasma FGF23 levels also increased during 
biochemical remission from 44.2 ± 12.2 to 84.0 ± 58.8 (p=0.017). Serum creatinine 
and plasma PTH concentrations, which may affect circulation sclerostin did not 
change significantly (68.8 ± 14.7 μmol/l  to 71.8 ± 14.1 μmol/l, p=0.59 and 4.9 ± 2.3 
pmol/l to 4.3 ± 2.1 pmol/l, p=0.60, respectively). 
The median time of blood sampling after surgical treatment was 3 months (range 1 
week to 18 months). There was a positive correlation between the percent changes 
in plasma sclerostin levels and time of surgery (r=0.68, p=0.015). There was no 
correlation between sclerostin levels and changes of bone turnover markers. 
Discussion
Since its discovery a decade ago, sclerostin has emerged as a key negative regulator 
of bone formation and glucocorticoids were reported to stimulate the expression of 
the SOST gene, which encodes sclerostin (3). Contrary to this finding, we show here 
that plasma sclerostin levels are significantly decreased in patients with endogenous 
hypercortisolism and increase after surgical treatment and achievement of clinical 
and biochemical remission. 
Table 1. mean age and biochemical parameters of patients with endogenous hypercortisolism 
and age-and-gender matched healthy controls
Chapter 6
controls patients p-value
male: female 5: 16 5: 16 -
Age (years) 41.6 ± 11.8 41.3 ± 12.7 0.66
P1NP (ng/ml) 44.9 ±14.3 36.9 ± 21.9 0.12
CTX (pg/ml) 224 ± 144 229 ± 224 0.94
Sclerostin (pg/ml) 207 ± 48 112 ± 49 <0.001
FGF23 (pg/ml) 37.5 ± 16.9 42.8 ± 12.1 0.25
Creatinine (μmol/l) 68.6 ± 12.8 66.9 ± 13.8 0.62
PTH (pmol/l) - 6.6 ± 3.1 -
Calcium (mmol/l) 2.25 ± 0.07 - -
Phosphate (mmol/l) 1.28 ± 0.14 - -
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In bone, sclerostin is exclusively produced by osteocytes (13), cells that are directly 
affected by glucocorticoids which promote their apoptosis (1). Recent evidence 
suggests that glucocorticoids may also induce autophagy in osteocytes (14), and/
or may increase oxidative stress (15). We, therefore, propose that the decreased 
sclerostin levels of patients with hypercortisolism are due to decreases in osteocytes 
function and/or number rather than to a direct, inhibitory, effect of glucocorticoids on 
sclerostin production. The increases in sclerostin levels during biochemical remission 
may be due either to the recovery of the function of the osteocytes, following the 
cessation of the metabolic stress, or to an increase in the number of osteocytes 
following the removal of the apoptotic effect of glucocorticoids
To further explore this notion, we measured circulating FGF23 in our patients before 
and after treatment. FGF23 is also produced by osteocytes but its production is not 
affected by glucocorticoids (3). It can, therefore, be considered as an independent 
parameter of the function and/or number of osteocytes. The observed, significant 
Figure 1. Mean (SD) levels of biochemical markers of bone turnover, sclerostin and FGF23 
in patients with endogenous hypercortisolism at baseline (black bars) and during biochemical 
remission (grey bars). *p<0.05
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increases in the levels of FGF23 after treatment strongly support the hypothesis 
that the increases in sclerostin levels represent a restoration of osteocyte numbers 
and/or function. Consistent with this hypothesis is also the observed increase in 
the biochemical markers of bone turnover. Improvement in osteocyte number and/
or function may be responsible for the reversibility of the fracture risk following 
discontinuation of glucocorticoid therapy (16). 
Bone loss following the exogenous administration of glucocorticoids is biphasic with 
an initial rapid phase occurring during the first months of treatment followed by a 
prolonged phase of much slower bone loss. It has been postulated that during the 
initial phase an imbalance between bone resorption and bone formation, in favor of 
resorption, is the predominant pathogenetic factor for bone loss while during the 
second, chronic, phase reduced bone formation and osteocyte apoptosis are the main 
determinants of bone strength (17). Our findings in patients with chronic endogenous 
hypercortisolism are consistent with this sequence of events.  Thus, in the presence 
of chronic glucocorticoid excess sclerostin does not seem to affect bone formation but 
its values in blood may be a measure of the function and/or number of osteocytes. 
However, sclerostin may very well be directly involved in the initial phase of bone loss 
induced by glucocorticoids. This could not be studied in our patients but we previously 
showed that treatment of a patient with sclerostin deficiency with prednisone reduced 
both resorption and formation markers and we suggested that sclerostin plays an 
important role in the modulation of bone resorption by glucocorticoids while it 
does not affect their action on bone formation (18). Furthermore, mice treated with 
dexamethasone were protected from glucocorticoid-induced bone loss, when they 
were simultaneously treated with a neutralizing antibody against sclerostin (7). In 
these mice the protective effect of the sclerostin antibody was mainly due to the 
stabilization of bone resorption, with no evident effect on bone formation. Sclerostin 
is thought to act predominantly as an inhibitor of bone formation but  a recent study 
has shown that sclerostin can also stimulate osteoclast differentiation and function, by 
a RANKL-mediated mechanism in osteocytes (19). In addition, inhibition of RANKL 
by OPG reduces the rate of osteocyte apoptosis in glucocorticoid-treated mice (20). 
Thus, although we found no evidence for a role of sclerostin in glucocorticoid-induced 
suppression of bone formation during long-standing endogenous hypercortisolism, 
sclerostin may play a role in the early phase of glucocorticoid-induced bone loss. 
Further studies are needed to address these questions.  
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In conclusion, in this study we found that patients with endogenous hypercortisolism 
have decreased circulating sclerostin levels, which increase during biochemical 
remission of the disease and  we propose that these changes in sclerostin levels are 
due to the detrimental effect of glucocorticoids on osteocytes rather than to a direct 
effect of glucocorticoids on sclerostin synthesis. 
References
 1.  Weinstein RS 2001 Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2:65-73
 2.  Canalis E, Mazziotti G, Giustina A, Bilezikian JP 2007 Glucocorticoid-induced osteoporosis: 
pathophysiology and therapy. Osteoporos Int 18:1319-1328
 3.  Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE 2008 Glucocorticoid excess 
in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged 
suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from 
glucocorticoid-treated mice. Arthritis Rheum 58:1674-1686
 4.  Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R 2005 Glucocorticoid suppresses 
the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun 
329:177-181
 5.  Humphrey EL, Williams JH, Davie MW, Marshall MJ 2006 Effects of dissociated 
glucocorticoids on OPG and RANKL in osteoblastic cells. Bone 38:652-661
 6.  Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by 
glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of 
glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
 7.  Marenzana M, Greenslade K, Eddleston A, Okoye R, Marshall D, Moore A, Robinson MK 
2011 Sclerostin antibody treatment enhances bone strength but does not prevent growth 
retardation in young mice treated with dexamethasone. Arthritis Rheum 63:2385-2395
 8.  Hardy R, Cooper MS 2009 Bone loss in inflammatory disorders. J Endocrinol 201:309-320
 9.  Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari 
NL, Evdokiou A, Atkins GJ 2009 Pro-inflammatory cytokines TNF-related weak inducer of 
apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-
dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 24:1434-1449
 10.  Netea-Maier RT, van Lindert EJ, den Heijer M, van der Eerden A, Pieters GF, Sweep CG, 
Sclerostin in endogenous hypercortisolism
114
Grotenhuis JA, Hermus AR 2006 Transsphenoidal pituitary surgery via the endoscopic 
technique: results in 35 consecutive patients with Cushing’s disease. Eur J Endocrinol 154:675-
684
 11.  van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, 
Papapoulos SE 2011 Patients with sclerosteosis and disease carriers: human models of the 
effect of sclerostin on bone turnover. J Bone Miner Res 26:2804-2811
 12.  McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R 2011 Determination of Serum and 
Plasma Sclerostin Concentrations by Enzyme-Linked Immunoassays. J Clin Endocrinol Metab 
96:1159-1162
 13.  van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wielt E, Karperien M, 
Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW 2004 Sclerostin is an osteocyte-
expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp 
Med 199:805-814
 14.  Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, Biswas SK, Lo WK, Jiang 
JX 2010 Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 25:2479-2488
 15  Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC 2011 Glucocorticoids and 
tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in 
osteoblasts. J Biol Chem 286:44326-44335
 16.  Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids 
and risk of fractures. J Bone Miner Res 15:993-1000
 17.  Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of 
steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066
 18.  van Lierop AH, Hamdy NA, Papapoulos SE 2010 Glucocorticoids are not always deleterious 
for bone. J Bone Miner Res 25:2796-2800
 19.  Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ 2011 Sclerostin 
Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway. PLoS 
One 6:e25900
 20.  Weinstein RS, O’Brien CA, Almeida M, Zhao H, Roberson PK, Jilka RL, Manolagas SC 2011 




Sclerostin in endogenous hypercortisolism

Chapter 7
Patients with primary hyperparathyroidism 










In vitro and in vivo studies in animal models have shown that parathyroid hormone 
(PTH) inhibits the expression of the Sost gene which encodes sclerostin, an osteocyte-
derived negative regulator of bone formation. We tested the hypothesis that chronic 
PTH excess decreases circulating sclerostin in humans. 
Design
We studied 25 patients with elevated serum PTH concentrations due to primary 
hyperparathyroidism (PHPT) and 49 patients cured from PHPT after successful 
parathyroidectomy (EuPTH). 
Methods
We measured plasma PTH and serum sclerostin levels and the serum markers of bone 
turnover alkaline phosphatase, P1NP, and β-CTX. 
Results
As expected by the design of the study, mean plasma PTH was significantly higher 
(p <0.001) in PHPT patients (15.3 pmol/l; 95%CI: 11.1-19.5) compared  to that 
of EuPTH controls (4.1 pmol/l; 95%CI: 3.6- 4.5). PHPT patients had significantly 
lower serum sclerostin values compared to EuPTH subjects  (30.5 pg/ml; 95%CI: 
26.0-35.1 vs 45.4 pg/ml; 95%CI: 40.5-50.2; p<0.001 ) and to healthy controls (40.0 
pg/ml; 95%CI: 37.1-42.9; p=0.01). Plasma PTH concentrations were negatively 
correlated with serum sclerostin values (r= -0.44; p<0.001). Bone turnover markers 
were significantly correlated with PTH, but not with sclerostin.
Conclusion
Patients with primary hyperparathyroidism have significantly lower serum sclerostin 
values compared to PTx controls with normal PTH concentrations. The negative 
correlation between PTH and sclerostin strongly suggests that SOST is downregulated 




Parathyroid hormone (PTH) exerts its calciotropic action by acting directly on bone 
and kidney and indirectly on the intestine to increase the transport of calcium to 
the circulation. The skeletal effect of PTH is to increase the rate of remodeling 
(1), and it is generally believed that this effect is achieved by the binding of PTH 
to its specific receptor (PTHR1) on stromal/osteoblastic cells of the bone marrow. 
This in turn stimulates the production of RANK-ligand (RANKL) and decreases 
that of its decoy receptor osteoprotegerin (OPG) (2-5). Recent in vitro and animal 
studies suggest, however, that at least some of the effects of PTH on bone are also 
exerted by specific binding of the hormone to PTHR1 in osteocytes, resulting in 
inhibition of the expression of the Sost gene (6-9). This gene encodes sclerostin, 
a protein exclusively expressed in osteocytes in the skeleton (10), which decreases 
bone formation by binding to LRP5/6, resulting in inhibition of the Wnt signaling 
pathway in osteoblasts (11, 12).
Whether chronic PTH excess has similar effects on sclerostin secretion in humans 
as in animal models has not so far been investigated. In the present study, we 
tested the hypothesis that chronic hypersecretion of PTH, as seen in patients with 
hyperparathyroidism, may decrease sclerostin secretion, and that PTH may thus 
represent a potential regulator of sclerostin production in humans. To this effect, we 
measured sclerostin in serum of patients with untreated primary hyperparathyroidism 
(PHPT) and in a control group of patients with PHPT after establishment of cure 
following parathyroidectomy (PTx). 
Subjects and Methods
a. Patients
Thirty-four consecutive patients with primary hyperparathyroidism (PHPT), which 
was untreated, persistent, or recurrent following parathyroidectomy (PTx), and 54 
patients cured after successful PTx (EuPTH) were studied. Inclusion criteria included 
willingness to participate in the study, no impairment in renal function (serum 
creatinine levels <120 µmol/l), adequate vitamine D status (25-hydroxy vitamin D 
levels >50nmol/l) and no use of bone and mineral metabolism modifying agents such 
as bisphosphonates, calcimimetics or glucocorticoids.
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We defined  PHPT as plasma PTH concentrations above the upper limit of the 
normal laboratory reference range (>8pmol/l) in the presence of increased serum 
calcium concentrations (>2.55 mmol/l).
Patients with EuPTH were included when cure was confirmed by post-operative 
normalization of serum PTH and calcium concentrations, which was sustained for at 
least 6 months after PTx.
As per inclusion criteria, 9 patients were excluded from the PHPT group, 3 because 
of impaired renal function and 6 because of use of bisphosphonates, and 6 were 
excluded from the EuPTH group because of use of bisphosphonates.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center, and informed consent was obtained from all patients.
b. Methods.
Serum biochemistry
Serum calcium adjusted for albumin binding, phosphate, and creatinine were 
measured by semi-automated techniques. Serum alkaline phosphatase activity 
(ALP) was measured using a fully automated P800 modulator system (Roche BV, 
Woerden, Holland). P1NP (a marker of bone formation) and β-CTX (a marker of 
bone resorption) were determined using the E-170 system (Roche BV, Woerden, 
Holland). Plasma PTH was measured using the Immulite 2500 (Siemens diagnostics, 
Breda, Holland) and serum 25-hydroxyvitamin D (25-OHD) was measured using 
the LIAISON® 25-OH Vitamin D TOTAL assay (DiaSorin S.A./N.V., Bruxelles, 
Belgium)
Sclerostin measurement
Sclerostin was measured in serum by an electrochemiluminescence assay (MSD® 
96-well MULTI-ARRAY® Human Sclerostin Assay, Gaithersburg, Maryland, USA) 
which uses two polyclonal antibodies raised against the whole sclerostin molecule. 
The sclerostin standard for the assay is produced in a NS0 derived myeloma cell 
line, and the purity is checked by SDS-PAGE gel with silver stain. In our hands, the 
precision and reproducibility of the assay were < 6% and  < 15% , respectively,  the 
detection limit was ± 1 pg/ml, and the detection range was 1 to 10,000 pg/ml.  
Sclerostin was measured in serum of 77 healthy subjects (30 male and  47 female, 
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aged 20 to 77 years). All had normal serum calcium concentrations, renal function 
and bone turnover and none were using bisphosphonates, the calcimimetic cinacalcet 
or glucocorticoids.  Sclerostin was detected in serum of all healthy subjects; mean 
40.0 pg/ml (95%CI = 37.1 - 42.9 pg/ml), range 12.4 to 68.19 pg/ml,  while it was 
undetectable in serum of  3 patients with sclerosteosis . 
c.  Statistical analysis
Data was analysed using SPSS 16.0 (SPSS Inc. Chicago, USA). Between groups 
differences in baseline characteristics and serum biochemistry were assessed by 
student’s t-test. Pearson correlation coefficients were calculated to assess correlations 
between PTH (after logarithmic transformation), sclerostin and biochemical markers 




There were no differences in age, gender, weight or BMI between patients with PHPT 
and EuPTH controls (table 1).
As expected by inclusion criteria, mean serum calcium and PTH concentrations were 
significantly higher and those of phosphate significantly lower in the PHPT group 
compared to the EuPTH group. There were no differences in serum 25-OHD or 
creatinine concentrations between the two groups.
Values are given as mean ± standard deviation. BMI = body mass index. * PHPT vs EuPTH
Table 1. Subject characteristics.
Sclerostin in primary hyperparathyroidism
PHPT EuPTH p-value*
Male : Female 10:15 13:36 0.41
Age (years) 59.6 ± 16.7 62.4 ± 10.9 0.44
Weight (kg) 80.0 ± 18.2 81.1 ± 15.3 0.78
BMI (kg/m²) 27.0 ± 6.0 28.1 ± 4.6 0.42
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Patients with PHPT had significantly higher levels of biochemical markers of bone 
formation (P1NP) and bone resorption (β-CTX) compared to EuPTH controls. 
Combining all patients, there was a significant positive correlation between plasma 
PTH concentrations and the concentrations of all three measured biochemical markers 
of bone turnover (ALP: r=0.23, p=0.047; P1NP: r=0.45, p<0.001; β-CTX: r=0.54, 
p<0.001). There was also a significant correlation between PTH and P1NP (r=0.51, 
p=0.009) in the PHPT group, but not between PTH and ALP (r=0.35, p=0.085), 
or PTH and β-CTX  (r=0.31, p=0.13). In the EuPTH group alone PTH was not 
correlated with any of the biochemical markers of bone turnover (Tabel 2). 
Serum sclerostin
Mean serum sclerostin level of patients with PHPT (30.5 pg/ml, 95%CI: 26.0-35.1) 
was significantly lower than that of patients with EuPTH and healthy controls 
(45.4 pg/ml, 95%CI: 40.5-50.2; p<0.001, and 40.0 pg/ml, 95%CI: 37.1-42.9; p=0.01, 
respectively) (Figure 1). There was no significant difference in mean sclerostin values 
between EuPTH and healthy subjects (p=0.13).
There was no significant correlation between PTH and sclerostin concentrations 
within each individual group of patients but there was a significant negative 
correlation between sclerostin and PTH when all patients were pooled together (r=-
0.44, p<0.001) (Figure 2).
There was no significant relationship between serum sclerostin and biochemical 
markers of bone turnover in patients with PHPT or in all patients combined. 
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Table 2. Biochemical measurements
Values are given as mean ± standard deviation.
PHPT = primary hyperparathyroidism; EuPTH= euparathyroid controls. 
* PHPT vs EuPTH
PHPT EuPTH Reference range p-value*
Calcium homeostasis
PTH (pmol/l) 15.3 ± 10.7 4.1 ± 1.6 1.5 - 8.0 <0.001
Calcium (mmol/l) 2.61 ± 0.13 2.26 ± 0.12 2.15 - 2.55 <0.001
Phosphate (mmol/l) 0.92 ± 0.14 1.14 ± 0.24 0.90 - 1.50 <0.001
25 (OH) D (nmol/l) 53.1 ± 34.3 53.9 ± 20.2 30 -120 0.90
Creatinine (μmol/l) 80.2 ± 18.1 76.8 ± 14.7 44 - 80 0.39
Bone turnover
ALP (U/l) 87.0 ± 23.0 75.7 ± 23.6 40 - 120 0.055
P1NP (ng/ml) 45.9 ± 16.9 34.0 ± 15.5 16 - 80 0.004
β-CTX (ng/ml) 0.32 ± 0.15 0.17 ± 0.11 0.01– 0.66 <0.001
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Figure 1. Serum sclerostin levels in PHPT, EuPTH and healthy subjects.
PHPT = primary hyperparathyroidism; EuPTH= euparathyroid controls. 
***  p <0.001 **  p =0.01 (student’s t-test).
Figure 2. Relationship between circulating sclerostin and PTH levels. 
r=-0.44 , p<0.001 (pearson’s correlation). PTH levels were log transformed because of skewness.
 PHPT = primary hyperparathyroidism; EuPTH = euparathyroid controls.
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Discussion
Data from our study demonstrate that in humans, chronic PTH excess as observed in 
patients with primary hyperparathyroidism, is associated with a significant decrease 
in circulating sclerostin and that there is a significant negative correlation between 
PTH and serum sclerostin levels. Taken together these results suggest that, similar 
to animal models (6-9), PTH has a regulatory role on sclerostin production also in 
humans.
Sclerostin, a glycoprotein expressed by osteocytes in bone and encoded by the SOST 
gene, has emerged in recent years as an important regulator of bone formation in 
humans as well as in animals (13, 14).  Inactivating mutations of the SOST gene 
leading to sclerostin deficiency have been shown to be associated with the rare skeletal 
disorder sclerosteosis, which is characterized by a marked increase in bone mass (13). 
Deletion of the Sost gene in mice have also been shown to increase bone formation, 
bone mass and bone strength (14). Moreover, inhibition of sclerostin secretion by a 
monoclonal antibody to sclerostin has been shown to increase bone formation and 
bone mass in rodents, primates and humans (14-16). Conversely, transgenic mice 
overexpressing Sost have low bone mass and impaired biomechanical competence (17). 
The mechanism of action of sclerostin to decrease bone formation involves inhibition 
of the Wnt signaling pathway (11, 12), although its precise molecular mechanism 
and factors controlling its secretion are as yet to be determined. Recent animal 
studies have shown that mechanical loading and high PTH levels downregulate the 
expression of Sost in osteocytes and decrease the production of sclerostin resulting in 
stimulation of bone formation (8, 18).
Human studies of sclerostin regulation have lagged behind due to lack of non-
invasive techniques to determine sclerostin production. A number of assays have been 
recently developed for the measurement of sclerostin in blood. In our study, we used 
a sclerostin assay which proved to have excellent performance characteristics in our 
hands. Sclerostin was detectable in serum in all healthy subjects studied, suggesting 
that the protein is secreted and enters the circulation, while it was undetectable 
in three patients with sclerosteosis in whom it was measured. We chose to study 
patients with primary hyperparathyroidism in order to mimic as closely as possible 
the effect of chronic PTH excess on sclerostin, as previously studied in animals (6, 8). 
In addition, we chose to use as controls patients with primary hyperparathyroidism 
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cured after parathyroidectomy to exclude potential confounding factors, other than 
PTH excess. 
We show here that serum sclerostin levels are significantly decreased in patients with 
chronic PTH excess due to PHPT compared to EuPTH and healthy subjects. PTH 
has been shown to decrease SOST transcription in vitro (6, 7), and continous and 
intermitent chronic administration of PTH to rodents is associated with decreased 
Sost mRNA and sclerostin expression in osteocytes (6, 7, 9). Moreover, transgenic 
mice expressing a constitutively active PTH receptor in osteocytes exhibit decreased 
expression of sclerostin and increased Wnt signaling associated with increased bone 
mass (8). Additional evidence for an interaction between PTH and Sost/sclerostin 
was recently provided by a study showing that the anabolic actions of PTH on 
bone was blunted in Sost-overexpressing mice (19). In keeping with the notion of 
a regulatory role of PTH for sclerostin production, our data show a significant 
correlation between circulating PTH and sclerostin. These data extend those of 
Mirza et al (20) who recently reported a negative relationship between serum PTH 
and sclerostin in healthy postmenopausal women, and those of  Drake et al (21), 
who showed that intermittent PTH treatment decreased serum sclerostin levels in 
postmenopausal women.
As expected in the presence of chronic PTH excess, patients with PHPT had increased 
bone turnover as indicated by increased biochemical parameters of bone formation 
and resorption. There was a significant relationship between circulating PTH 
concentrations and serum P1NP and β-CTX. We did not however, find a significant 
relationship between biochemical parameters of bone turnover and serum sclerostin, 
either in patients with PHPT or the combined group of PHPT and EuPTH subjects. 
This lack of correlation between sclerostin and bone turnover markers was previously 
reported in healthy postmenopausal women (20).
The actions of PTH on bone are complex and involve a variety of signaling pathways in 
bone marrow stroma cells, osteoblasts and osteocytes (22, 23). Despite the significant 
progress in our understanding of the actions of PTH on bone it should be appreciated 
that the cellular and molecular actions of PTH, which determine the action of the 
hormone on bone remodeling and bone balance have only been partially unraveled 
and studies are needed to further elucidate these actions.
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Patients with Type 2 Diabetes Mellitus (T2DM) have an increased risk of fractures 
and thiazolidinediones (TZDs) increase this risk. TZDs stimulate the expression of 
sclerostin, a negative regulator of bone formation, in vitro.  Abnormal sclerostin 
production may, therefore, be involved in the pathogenesis of increased bone fragility 
in patients with T2DM treated with TZDs. 
Methods
We measured serum sclerostin, P1NP and CTX  in 71 men with T2DM treated with 
either pioglitazone (PIO) 30 mg once daily, or metformin (MET) 1000mg twice daily. 
Baseline values of sclerostin and P1NP were compared to those of 30 healthy male 
controls
Results 
Compared to healthy controls, patients with T2DM had significantly higher serum 
sclerostin levels (59.9 pg/ml vs 45.2 pg/ml, p<0.001), but similar serum P1NP levels 
(33.6 ng/ml vs 36.0 ng/ml, p=0.39).  After 24 weeks treatment, serum sclerostin 
levels increased by 11%  in PIO-treated patients, and decreased by 1.8%  in MET-
treated patients (p=0.018). Changes in serum sclerostin were significantly correlated 
with changes in serum CTX in all patients (r=0.36, p=0.002), and in PIO-treated 
patients (r=0.39, p=0.020), but not in MET-treated patients (r=0.17, p=0.31).
Conclusions
Men with T2DM have higher serum sclerostin levels than healthy controls and 
these levels further increase after treatment with PIO, which is also associated with 
increased serum CTX. These findings suggest that increased sclerostin production 
may be involved in the pathogenesis of increased skeletal  fragility in patients with 





Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fractures 
(1) but the mechanism(s) responsible for the increased bone fragility remain unclear. 
Moreover, blood glucose lowering therapy using thiazolidinediones (TZDs), has also 
been reported to cause bone loss (2) and to further increase the risk of fractures (3, 
4). Activation of PPAR-γ and preferential stimulation of the differentiation of bone 
marrow mesenchymal stem cells into adipocytes at the expense of osteoblasts has 
been proposed as potential mechanism for these effects of TZDs on bone (5). TZDs 
have also been recently reported to stimulate sclerostin synthesis in vitro, suggesting 
an additional mechanism for the detrimental effects of TZDs on bone (6). Sclerostin 
is a glycoprotein synthesized in bone by osteocytes which reduces bone formation 
(7, 8) and serum sclerostin levels have been found to be significantly correlated with 
fracture risk in postmenopausal women (9). Abnormal sclerostin production may 
contribute to the pathogenesis of bone fragility of patients with T2DM as well as in 
the  actions of TZDs on bone. To test this hypothesis we measured serum sclerostin 
and biochemical markers of bone turnover in men with T2DM before and after 
treatment with the TZD pioglitazone.
Patients and Methods
We studied 71 men with T2DM who participated in the PIRAMID study  (Pioglitazone 
Influence on Triglyceride Accumulation in the Myocardium in Diabetes). The design 
and results of this study (10) as well other metabolic parameters of the patients 
including whole body insulin sensitivity (11) have been reported previously. In brief, 
this was a 24-week prospective, randomized, double-blind, double-dummy with active 
comparator, 2-center parallel group intervention study.  Men with uncomplicated 
T2DM, aged 45 to 65 years, were included in the study. After a 10-week wash out 
period of previous medications, patients were treated with glimepiride for 8 weeks 
and were subsequently randomized to pioglitazone (15mg once daily, titrated to 30 
mg once daily after 2 weeks) or metformin (500 mg twice daily, titrated to 1000 mg 
twice daily) and matching placebo to be taken in addition to glimepiride throughout 
the study. Blood samples were taken after an overnight fast at baseline and after 24 
weeks of treatment and were stored at -80 C until assayed .
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Baseline data including serum sclerostin and P1NP values were compared to those 
of 30, previously described,  healthy male volunteers (12). All of these subjects had 
normal serum calcium concentrations, renal function and bone turnover markers and 
were not using medications that could affect calcium or bone metabolism.
The study was approved by the Medical Ethics Committees of the two participating 
Centers and informed consent was obtained from all participants in the study. 
 
Serum biochemistry
Sclerostin was measured by a highly sensitive electrochemiluminescence assay 
(Mesoscale discoveries, Gainsburg, USA) as previously described  (13). The intra-
precision of the assay was 6% and the inter-precision 10%. All samples from individual 
patients were measured in the same assay. Serum calcium adjusted for albumin 
binding, phosphate, and creatinine were measured by semi-automated techniques. 
Procollagen Type 1 Amino-terminal Propeptide (P1NP) and carboxy-terminal cross-
linking telopeptide of type I collagen  (CTX) were measured by the E-170 system 
(Roche BV, Woerden, Holland). 
Statistical analysis
Data are expressed as mean ± standard deviation (unless otherwise stated). Absolute 
changes and percentage changes in biochemical parameters between baseline and 
end-of-study values were calculated for each subject. Differences between groups 
were assessed by student’s t- tests. Differences in sclerostin levels between patients 
and healthy controls were corrected for BMI and weight using a linear mixed model. 
Within treatment group differences in percentage changes in measured parameters 
were tested by one-sample t-test . Correlations were assessed by Pearsons correlation 
tests. Statistical analysis was performed using the SPSS 17.0 software (SPSS Inc. 
Chicago, USA). A p-value of <0.05 was considered to be statistically significant. 
Results       
Baseline 
Mean age of patients with T2DM (56.5 ± 5.6 years ) was comparable to that of 
controls (55.0 ± 16.4 years, p=0.50), but patients were heavier (patients: 92.2 ±13.6 
kg, controls: 80.7 ± 12.1 kg,  p<0.001) and had a higher BMI (patients: 28.7 ± 3.4 
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kg/m2, controls: 25.4 ± 4.0 kg/m2,   p<0.001) (Table 1). 
Patients with T2DM had significantly higher serum sclerostin levels compared to 
healthy controls (59.9 pg/ml; 95%CI: 55.2 - 64.8 pg/ml vs  45.2 pg/ml; 95%CI: 40.6 
- 49.8 pg/ml, p<0.001) (Figure 1A). This difference in sclerostin levels remained 
significant after adjusting for BMI or weight (p=0.008). In patients with T2DM, 
serum sclerostin levels were positively correlated with serum fasting insulin levels 
(r=0.41, p<0.001), but not with HbA1c (r=0.07, p=0.57), weight (r=0.07, p=0.58) or 
BMI (r=0.18, p=0.12).  There was no difference in mean serum P1NP levels between 
patients and controls (33.6 ng/ml; 95%CI: 31.0 - 36.6 ng/ml; and 36.0 ng/ml; 95%CI: 
30.7 - 40.8 ng/ml respectively, p=0.39) (Figure 1B).  
Response to treatment
There was no significant difference in age, weight and time since diagnosis of T2DM 
between the two treatment groups (Table 2). Baseline values and changes of plasma 
glucose, insulin, and HbA1C after 24 weeks of treatment have been previously 
reported (10). Baseline values were similar in the two treatment groups and improved 
significantly, resulting in a similar degree of glycemic control during the 24 weeks of 
Table 1. Baseline anthropometric and biochemical data of male patients with T2DM and 
healthy controls. Values are given as mean  ± standard deviation.
Sclerostin in type 2 diabetes mellitus
Controls (n=30) Patient (n=71) p-value
Age (years) 55.0 ± 16.4 56.5 ± 5.6 0.59
Weight (kg) 80.7 ± 12.1 92.2 ± 13.6 <0.001
BMI (kg/m²) 25.4 ± 4.0 28.6 ± 3.3 <0.001
Sclerostin (pg/ml) 45.2 ± 12.8 59.2 ± 19.4 <0.001
P1NP (ng/ml) 36.0 ± 13.8 33.8 ± 12.2 0.43
CTX (pg/ml) - 311 ± 14
Calcium (mmol/l) 2.27 ± 0.10 2.29 ± 0.10 0.36
Phosphate (mmol/l) 1.05 ± 0.12 0.99 ± 0.17 0.41
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treatment with either metformin or pioglitazone.
Baseline values of serum sclerostin and of biochemical markers of bone turnover and 
calcium metabolism were similar between the two treatment groups (Table 2). The 
two treatment regimens had, however, different effects on serum sclerostin and bone 
marker levels (Figure 2). Serum sclerostin levels increased by 11% (95%CI: 2.26-
19.8%, p=0.019) after 24 weeks of treatment with pioglitazone, but there was no 
significant change in these levels in patients treated with metformin (-1.8%; 95%CI: 
-8.8-5.0%, p=0.42). The difference in sclerostin response between the two treatment 
groups was significant (p=0.018). 
Serum P1NP levels increased by 3.7% (95%CI: -3.9%-11.3%, p=0.35) in the pioglitazone 
group, but decreased significantly by 19.1% (95%CI: -25.5%--12.8%, p<0.001) in the 
metformin group (between group difference p<0.001). Serum CTX levels increased 
by 16.8% (95%CI:4.4%-29.1%, p=0.012) after treatment with pioglitazone, but 
decreased by 19.0% (95%CI:-27.1%--10.9%, p<0.001) in the metformin treated 
group (between group difference p<0.001). There was no significant change in serum 
calcium, phosphate or creatinine concentrations after 24 weeks of treatment with 
either agent.
Figure 1. Serum sclerostin (A) and P1NP (B) levels in male patients with type 2 diabetes 
mellitus and healthy male controls. Bars represent standard error of the mean. 
p-values: significance of differences between groups (student’s t-tests). n.s.: non-significant
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Table 2. Baseline anthropometric and biochemical data of male patients with T2DM treated 
with either metformin or pioglitazone. Values are given as mean ± standard deviation.
Figure 2. Mean percentage changes of serum levels of sclerostin, P1NP, and CTX in male 
patients with T2DM treated with metformin (open circles), or pioglitazone (closed squares)
Bars represent the 95% confidence interval 
*: significance of change from baseline within groups (one-sample t-test), p<0.05
p-values: significance of differences between groups (student’s t-tests)






Age (years) 56.5 ± 5.4 56.4 ± 5.9 0.99
Weight (kg) 93.2 ± 14.6 91.1 ± 12.6 0.50
BMI (kg/m²) 29.3 ± 3.8 28.2 ± 3.0 0.17
Time since diagnosis (years) 3.6 ± 2.5 4.6 ± 2.8 0.11
Sclerostin (pg/ml) 62.4 ± 18.9 58.5 ± 22.0 0.42
P1NP (ng/ml) 35.1 ± 11.7 32.0 ± 12.7 0.28
CTX (pg/ml) 381 ± 380 294 ± 140 0.40
Calcium (mmol/l) 2.29 ± 0.10 2.28 ± 0.11 0.92
Phosphate (mmol/l) 1.00 ± 0.16 1.00 ± 0.18 0.60
Creatinine (μmol/l) 76.6 ± 17.3 77.3 ± 12.7 0.49
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Relationship between serum sclerostin and markers of bone turnover
There was no significant relationship between serum sclerostin levels and either serum 
P1NP (r=0.15, p=0.22) or serum CTX (r=0.17, p=0.17) at baseline. There was also 
no significant correlation between changes in serum sclerostin values and changes in 
serum P1NP levels in all patients pooled together (r=0.12, p=0.31), or in individual 
treatment groups (metformin: r=0.02, p=0.90; pioglitazone: r=0.05, p=0.77) (Figure 
3A). In contrast, changes in serum sclerostin levels were significantly correlated with 
changes in serum CTX levels in all patients pooled together (r=0.36, p=0.002), and 
in pioglitazone treated patients (r=0.39, p=0.020), but not in the metformin treated 
patients (r=0.17, p=0.31) (Figure 3B). 
Figure 3.  Relationship  between changes of  serum levels of sclerostin and P1NP (A) and CTX 





We show here that circulating sclerostin levels are increased in patients with 
uncomplicated type 2 diabetes mellitus and respond differently to different blood 
glucose lowering medications. In the presence of similar control of glycaemia, metformin 
treatment given for 24 weeks had no effect on sclerostin levels and significantly 
decreased levels of biochemical markers of bone turnover, whereas pioglitazone 
treatment increased the serum levels of sclerostin and the bone resorption marker 
CTX.
The exact pathogenesis of increased bone fragility observed in patients with T2DM 
remains unclear. In these patients it is well established that fractures occur at higher 
bone mineral density (BMD) values than in patients with osteoporosis. The increased 
fracture rate has also been found to be independent of the increased frequency 
of falls, also documented in patients with T2DM (1, 14, 15). Changes in calcium 
homeostasis, increased secretion of inflammatory cytokines and the accumulation of 
advanced glycation end-products have all been proposed as contributory factors to 
the pathogenesis of increased bone fragility in T2DM (16, 17). The identification of 
osteocyte-produced sclerostin as a key regulator of bone formation by osteoblasts 
has initiated a number of studies of the effect of this protein on bone strength. 
Lack of sclerostin leads to profound increases in bone mass in humans (13, 18) 
and in animal models (19), whereas overexpression of sclerostin is associated with 
decreased mechanical strength in animal models (8). In a recent study circulating 
sclerostin levels were positively associated with fracture risk in a large cohort of 
postmenopausal women (9). Moreover, established determinants of bone strength 
such as mechanical loading, parathyroid hormone and estrogen have been shown 
to modulate the production and/or the secretion of sclerostin (12, 20, 21). Our 
study findings of increased serum sclerostin levels in patients with T2DM suggest a 
potential role for this protein in bone metabolism in T2DM by an as yet unidentified 
mechanism. The positive correlation between serum sclerostin and insulin levels 
suggests a possible contribution of insulin in the production and/or secretion of 
sclerostin. However, in contrast to the case of osteoblasts, few or no insulin receptors 
could be detected in osteocytes by immunohistochemical staining (22). In our 
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patients with T2DM the documented increase in serum sclerostin levels was not 
associated with a decrease in serum levels of the bone formation marker P1NP, in 
agreement with a previous study (23) . Another marker of bone formation osteocalcin, 
particularly the undecarboxylated form, has been implicated in the regulation of 
insulin secretion (24). However, measurements of serum osteocalcin in patients with 
T2DM have provided conflicting results showing either no change or decrease (23, 
25-29). We did not measure serum osteocalcin but a significant positive relationship 
with serum P1NP has been previously reported in patients with T2DM (23, 28). 
Notwithstanding, our findings are in keeping with a recent study which reported 
higher serum sclerostin levels in patients with T2DM compared to controls but no 
difference in the bone formation markers serum osteocalcin and bone specific alkaline 
phosphatase between T2DM patients and healthy controls (26). 
In our cohort of T2DM patients, treatment with metformin or pioglitazone in 
combination with glimepiride, improved glucose regulation to a similar degree, but had 
different effects on serum sclerostin levels and biochemical markers of bone turnover. 
Treatment with metformin for 24 weeks had no apparent effect on serum sclerostin 
levels, but significantly decreased bone turnover, as assessed by serum markers of 
bone formation (P1NP) and bone resorption (CTX). A decrease in bone turnover has 
been previously reported after metformin treatment (30, 31), but a similar decrease 
in bone turnover has also been noted after improvement of glycemic control using 
other therapeutic regimens, such as diet or insulin administration (32). However, the 
different effects on bone turnover observed in our study in the pioglitazone treated 
patients despite a similar control of glucose metabolism demonstrate  that the two 
agents have different effects on bone metabolism that are independent of their 
glucose-lowering action.
 
Our data indeed show that in contrast to metformin, serum sclerostin levels increased 
in patients treated with pioglitazone and that this was associated with a significant 
increase in serum CTX levels, despite adequate glycemic control. Over the past 
decade evidence has been accumulating on the detrimental effect of thiazolidinediones 
(TZDs) on the skeleton, decreasing bone mass and increasing fracture risk in both 
men (33-35) and women with diabetes mellitus (4, 33, 35-39). This deleterious effect 
of TZDs on the skeleton is generally attributed to the activation of PPAR-γ in the 
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bone marrow by these agents, leading to preferential stimulation of adipogenesis at 
the cost of osteoblastogenesis (5). Our results suggest another potential pathogenetic 
mechanism, namely stimulation of sclerostin production by TZDs.  This finding 
conforms with recent in vitro data by Mabbilieau et al.  who showed that TZDs 
stimulate the expression of sclerostin by osteocytes in the absence of 17β-estradiol 
(6). Although sclerostin is a well established inhibitor of bone formation, recent 
evidence indicates that it can also promote osteoclastogenesis by stimulating RANKL 
produced by osteocytes (40).  Moreover, inhibition of sclerostin in animals and 
humans by a specific antibody does not only lead to increased bone formation but 
also to decreased bone resorption (41, 42). Taken together, these data suggest that 
pioglitazone stimulates the production of sclerostin, which would in turn increase 
RANKL production by osteocytes, thus resulting in a dual effect on bone metabolism, 
reducing bone formation and increasing bone resorption, which could explain the 
adverse effect of pioglitazone on bone quality.
A limitation of our study is that it was conducted only in men with uncomplicated 
T2DM and our results cannot be readily extrapolated to all patients with T2DM. 
The study was of short duration precluding the assessment of the effect of TZDs on 
BMD or fracture risk
Notwithstanding, our study shows that patients with T2DM have increased circulating 
sclerostin levels which might contribute to the documented increased bone fragility 
of these patients. Of particular clinical relevance is the finding that metformin and 
pioglitazone have different effects on sclerostin levels and biochemical markers of 
bone turnover, with metformin having a clearly more favorable bone profile.  
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Serum sclerostin levels in Paget’s disease and 
prostate cancer with bone metastases with 









Evidence has been accumulating for the role of osteocytes as key players in the 
regulation of bone remodeling. One of the main products of these cells, sclerostin, 
inhibits bone formation and may also stimulate bone resorption. Circulating sclerostin 
has been evaluated in humans, but data are scarce in patients with different rate of 
bone turnover. To address this issue we evaluated serum sclerostin levels in patients 
with Paget’s disease of bone (PD) and in patients with prostate cancer metastatic to 
the skeleton (PC). 
Sclerostin levels were measured in 88 patients with PD, 20 patients with PC and 237 
healthy individuals (113 men and 124 women, aged 20 to 77). Bone turnover was 
evaluated by measuring serum levels of procollagen type 1 amino-terminal propeptide 
(P1NP) in all individuals studied and β-carboxy-terminal cross-linking telopeptide 
of type I collagen (β-CTX) only in patients. Patients were aged between 45 and 88 
years and had a wide range of bone turnover: serum P1NP 9.2 to 1872 ng/ml and 
β-CTX 50 to 3120 pg/ml. Patients with PD and with PC had significantly higher 
mean serum sclerostin levels (53.1 ± 22.7 pg/ml and 56.6 ± 25.8 pg/ml, respectively) 
compared to healthy controls (38 ± 12.1 pg/ml) (p<0.001). Serum sclerostin levels 
were significantly correlated with P1NP in all (n=345) studied subjects (r=0.32, 
p<0.001)  Circulating sclerostin levels are significantly increased in patients with 
increased bone turnover, regardless of underlying pathology. These increased levels 
may be due to a compensatory response to the increased number of osteoblasts at 





Osteocytes are former osteoblasts embedded in lacunae of the mineralized bone 
matrix. Over the last decade evidence has unfolded about the critical role of these 
abundant bone cells as orchestrators of bone remodeling through regulation of 
both osteoblast and osteoclast activity, and as endocrine regulators of phosphate 
homeostasis [1]. Osteocytes communicate with each other and with other cellular 
components of bone through an extensive network of cytoplasmic processes, thereby 
fine tuning the differentiation and function of these cells. 
One of the main secreted products of osteocytes, sclerostin, is solely expressed by 
mature cells and is considered a major negative local regulator of bone formation 
[2, 3] . This takes place primarily through binding with the low-densitity lipoprotein 
receptor-related protein 5 and 6 (LRP5/6) co-receptors and consequently inhibiting 
the canonical Wnt signaling pathway [4, 5]. Sclerostin has attracted much attention 
over the last few years due to its implication in the pathogenesis of two rare skeletal 
disorders characterized by substantial increase in bone mass, sclerosteosis and van 
Buchem disease [6-9]. In addition, suppression of sclerostin production is, at least 
partly, responsible for the anabolic effect of mechanical loading and PTH on bone 
[10-12].
Apart for its well documented role as an inhibitor of bone formation, sclerostin is also 
involved in the regulation of bone resorption. Recent evidence indicates that osteocytes 
are the main source of RANKL in the skeleton [13, 14] and that sclerostin promotes 
osteoclast formation and activity by osteocytes in a RANKL-dependent manner 
[15]. Moreover, a neutralizing antibody against sclerostin increased significantly the 
rate of bone formation in animal models while it did not change or decreased bone 
resorption, assessed histomorphometrically [16, 17].  Finally, in a phase 1 clinical 
trial a single parenteral administration of an antibody to sclerostin led to a rapid and 
dose-dependent increase in serum P1NP and decreased serum CTX [18].
To obtain more insight into the relationships between sclerostin and bone remodeling 
in humans, we evaluated serum sclerostin levels in patients with Paget’s disease of 
bone, characterized by predominantly increased bone resorption, at different stages 
of disease activity, and in patients with prostate cancer metastatic to the skeleton 
mainly characterized by increased bone formation, at different degrees of skeletal 
involvement.




Eighty eight patients with biochemical, radiological and scintigraphic evidence for 
Paget’s disease of bone and 20 patients with histological and scintigraphic evidence 
for prostate cancer metastatic to the skeleton, who were under regular control in the 
Outpatient Clinic of the Department of Endocrinology and Metabolic Diseases of the 
Leiden University Medical Center were included in the study. Exclusion criteria were 
impaired renal function (serum creatinine >120 μmol/l), impaired liver function, or 
the presence of diseases known to increase bone turnover other than Paget’s disease 
of bone and prostate cancer. Stored at -80°C and previously unthawed serum samples 
were measured for sclerostin, the bone formation marker procollagen type 1 amino-
terminal propeptide (P1NP) and the bone resorption marker β-carboxy-terminal 
cross-linking telopeptide of type I collagen (β-CTX). 
Subject characteristics
Of the 88 patients with Paget’s disease of bone, 47 had monostotic (predominantly 
pelvis) and 41 had polyostostic disease (ranging from 2 to 8 affected skeletal sites). 
Twenty four patients were treatment–naïve at the time of sampling and 64 had been 
previously treated with one or more (median 2) courses of  bisphosphonates (short 
courses of intravenous pamidonate 45, olpadronate 46, EB-1053 4, zoledronate 1; 
monthly courses of oral olpadronate  3 , oral etidronate 8 )  Twenty eight  of these 
patients had received treatment within the last 4 years, and 36 received their last 
course of treatment more than 5 years before the time of sampling (range 5 to 25 
years). All patients with metastatic prostate cancer were androgen-deprived and 
bisphosphonate-treatment naïve at time of sampling. 
Serum sclerostin levels obtained from patients were compared with those obtained 
from two cohorts of healthy individuals, who were used as controls. The first, 
previously described, cohort consisted of 72 healthy volunteers, 29 males and 43 
females, with a mean age of 50.4 years (range: 20-77 years) [19] . The second cohort 
consisted of 165 healthy individuals, 84 males and 81 females, with a mean age of 65.1 
years (range 63-68 years) studied in collaboration with the Division of Bone Diseases 
of the University of Geneva [20] (20).  All subjects had normal renal function and had 
Chapter 9
151
serum P1NP values below 65 ng/ml.
The study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and the Geneva University Hospitals and informed consent was 
obtained from all participants.
Biochemical assays
Serum calcium, phosphate and creatinine were measured by semi-automated 
techniques. Serum alkaline phosphatase activity (ALP) was measured using a fully 
automated P800 modulator system (Roche BV) and 25-hydroxyvitamin D (25-OHD) 
by the Liason 25-OHD assay (DiaSorin SA). Plasma PTH was measured by limulite 
2500 (Siemens Diagnostics). Serum P1NP and β-CTX were determined using the 
E-170 system (Roche BV). 
Sclerostin assay
Sclerostin was measured in serum by an electrochemiluminescence assay (MSD 96-well 
MULTI-ARRAY Human Sclerostin Assay, Gaithersburg, MD, USA), as previously 
described [21]. In brief, the sclerostin standard for the assay was produced in an 
NSO-derived myeloma cell line, and was checked for purity by SDS–PAGE gel with 
silver stain. The intra- and inter–assay coefficients of variation were 6% and 10% 
respectively. The detection limit of the assay was 1 pg/ml, and the detection range 
was 1–10 000 pg/ml. Using this assay, sclerostin was detected in the serum of all 
healthy subjects and was undetectable in the serum of 19 patients with sclerosteosis 
[21].
Statistical analysis 
Data are expressed as mean ± Standard Deviation (SD). Normality of distribution was 
assessed by Kolmogorov–Smirnov test and log-transformation of data was applied for 
non-normally distributed variables. Student’s t-test for independent samples or One-
way ANOVA was used for differences between groups, as applicable. Pearson’s X2 
test was applied to explore associations between sclerostin values and bone markers 
in serum. A probability level of random difference of 0.05 was considered significant. 
Data were analyzed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
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Results
The patient population studied consisted of 108 subjects (75 men and 33 women) 
with a mean age of 68.1 years (range 45 to 88 years). Demographic characteristics 
and laboratory values are shown in Table 1. As intended by study design, there was a 
wide range of bone turnover within the patient population, with serum P1NP ranging 
from 9.2 to 1872 ng/ml (mean 223.3 ng/ml) and β-CTX ranging from 50 to 3120 
pg/ml (mean 642.0 pg/ml) (Figure 1). There was a significant correlation between 
serum levels of β-CTX and P1NP in the whole patient population studied (r=0.78, 
p<0.001), as well in the two separate patient groups (Paget’s disease of bone: r=0.69, 
p=<0.001, bone metastatic disease: r=0.86, p<0.001). 








Number 88 20 237 -
Male : female 55:33 20:0 113:124 -
Age (yrs) 67.4 ± 10.6 71.1 ± 7.3 60 ± 11.3 -
BMI (kg/cm2) 27.6 ± 4.1 26.4 ± 3.7 25.1 ± 4.3 -
P1NP (ng/ml) 158 ± 235 511 ± 441 35.6 ± 12.7 < 65
ALP (U/l) 196 ± 248 834 ± 900 65.3 ± 16.31 40 – 120
β-CTX (pg/ml) 498 ± 330 1,275 ± 806 - < 590
Calcium (mmol/l) 2.37 ± 0.14 2.26 ± 0.12 2.27 ± 0.081 2.15 – 2.55
Phosphate (mmol/l) 1.05 ± 0.17 1.09 ± 0.27 1.07 ± 0.15 0.90 – 1.50
Creatinine (μmol/l) 88.4 ± 13.5 81.2 ± 16.6 77 ± 15 44 – 120
25-OH D (nmol/l) 58.6 ± 28.6 55.3 ± 24.9 - > 50
PTH (pmol/l) 6.6 ± 3.6 5.0 ± 1.6 - 1.5 -8.0
1Values obtained in a subset of the sohort (LUMC)
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Circulating sclerostin levels
In patients, mean serum sclerostin level was 53.8 pg/ml (range 11.9 pg/ml to 135.2 
pg/ml) and was significantly higher (p<0.001) than the mean value of sclerostin of all 
237 healthy controls (38.1 pg/ml; range 12.4 pg/ml to 80.1 pg/ml) (Figure 2). In both 
patients and healthy individuals there was no correlation between serum sclerostin 
levels and age. 
Paget’s disease of bone
In patients with Paget’s disease sclerostin levels ranged from 11.9 to 135.2 pg/ml, 
with the mean level being significantly higher than that of healthy controls (53.1 
pg/ml vs 38.0 pg/ml respectively, p<0.001). Because of the predominance of elderly 
men in the Paget’s cohort, results were also analyzed according to gender and age 
(younger or older than 65 years). Results showed that the difference in sclerostin 
values remained robust (Table 2) There was no significant difference in mean levels of 
Figure 1. Serum levels of P1NP and β-CTX in patients with Paget’s disease of bone, and prostate 
cancer with bone metastasis. Open circles Paget’s disease of bone, closed circles bone metastatic 
disease from prostate cancer. (r=0.78, p<0.001).
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sclerostin between previously bisphosphonate-treated and bisphosphonate-treatment 
naïve patients (55.2 pg/ml vs. 47.5 ng/ml respectively, p=0.16), while these were 
higher in patients with polyostotic compared to monostotic disease (59.0 pg/ml vs. 
48.1 pg/ml, p=0.024).
 
Prostate cancer metastatic to the skeleton
In patients with prostate cancer metastatic to the skeleton serum sclerostin levels 
ranged from 19.4 pg/ml to 120.5 pg/ml, with a mean level significantly higher than 
that of healthy controls (57.6 vs. 38.1 pg/ml, respectively, p=0.005). This difference 
remained significant when values of patients were compared to those of healthy males 
or  males older than 65 years (Table 2). There was no difference in mean sclerostin 
levels between patients with prostate cancer metastatic to the skeleton and those 
with Paget’s disease of bone (p=0.55). 
Relationship between sclerostin levels and biochemical markers of bone turnover. 
There was a significant relationship between serum sclerostin and serum P1NP in 
studied subjects (n=345, r=0.31, p<0.001). In patients with Paget’s disease alone, 
there was no relationship between serum sclerostin and P1NP levels (r=0.08, 
p=0.45). In contrast, in patients with prostate cancer serum levels of sclerostin were 
significantly correlated with those of P1NP (r=0.56,. p=0.01), Circulating sclerostin 
levels were not correlated with levels of β-CTX in the whole patient population 
(r=0.16, p=0.09), or in patients with Paget’s disease (r=0.08, p=0.46), but were 
correlated in patients with prostate cancer (r=0.48, p=0.03). 
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Figure 2. Serum sclerostin levels in healthy controls, and patients with Paget’s disease of bone, 
and prostate cancer with bone metastasis. *: p<0.01 compared to healthy controls
Subjects all >65years men men >65 years
Healthy 38.1 ± 12.1 38.3 ± 9.9 40.2 ± 12.5 39.8 ±10.2
(n=237) (n=102) (n=113) (n=55)
Paget’s disease 53.1 ±22.7* 53.5 ± 25.3* 55.4 ± 24.1* 55.8 ± 27.6*
(n=88) (n=54) (n=55) (n=33)
Prostate cancer 56.6 ± 25.8* 54.9 ± 22.8* 56.6 ± 25.8* 54.9 ± 22.8*
(n=20) (n=16) (n=20) (n=16)
Table 2. Serum sclerostin in healthy individuals and patients with Paget’s disease and prostate 
cancer metastatic to bone. 
* p<0.05 compared to healthy controls
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Discussion
Sclerostin is an osteocyte-produced local regulator of bone remodeling affecting 
both osteoblast and osteoclast function [2, 3, 15]. A previous study has shown 
that there is a strong relationship between circulating and bone marrow plasma 
levels of sclerostin consistent with the findings that osteocytes are the major source 
of sclerostin production and, therefore, the sclerostin present in peripheral blood 
[22]. Our data show that circulating levels of sclerostin are significantly increased 
in diseases associated with increased bone turnover, such as Paget’s disease and 
prostate cancer metastatic to the skeleton, regardless of the underlying pathogenetic 
mechanism responsible for the increased bone turnover. 
In Paget’s disease of bone, bone resorption is increased and is followed by increased 
and disorganized bone formation. In prostate cancer, skeletal metastases are mainly 
osteoblastic but increased bone resorption has also been biochemically, as also 
Figure 3. Relationship between serum levels of sclerostin and P1NP (A) and sclerostin and CTX 
(B) in patients with Paget’s disease of bone (open circles and solid line) and prostate cancer with 
bone metastasis (closed circles and interrupted line).
Chapter 9
157
shown here, and histologically documented [23-27]. Despite the difference in the 
pathogenetic mechanisms of Paget’s disease of bone and prostate cancer metastatic to 
the skeleton, both disorders share the common end-result of increased bone turnover. 
We found increased circulating sclerostin levels in both diseases compared to healthy 
controls which were independent of renal function, age and previous bisphosphonate 
treatment. All subjects included in our study had normal renal function and it was 
recently shown that serum sclerostin levels increase sharply in subjects with renal 
impairment (CKD 3 stage) [28]. We did not find any association of serum sclerostin 
levels with age consistent with some [29-33] but not other [28, 34-38] reports which 
may reflect differences in the characteristics of studied cohorts and/or specificity of 
sclerostin assays. Finally, previous bisphosphonate treatment of patients with Paget’s 
disease had no effect on sclerostin levels which may be due to inability of used 
bisphosphonates to reach the osteocytes and/or the long interval following the short 
exposure to the agents in our study. In orevious studies of patients with osteoporosis 
serum sclerostin did not change during treatment with alendronate [32] while they 
increased during treatment with risendronate or niridronate given intramuscularly 
[30, 39].
We found, in addition, a significant positive relationship between sclerostin levels and 
bone turnover markers in metastatic prostate cancer but not in Paget’s disease of 
bone. Although this result may reflect the difference in underlying pathophysiology 
between the two disorders, it remains difficult to draw any conclusion about the 
exact mechanism which regulates sclerostin production in these conditions. We could 
speculate, however, that in both diseases osteocytes may secrete more sclerostin as a 
compensatory response to the increased number of osteoblasts that are recruited to 
the affected skeletal sites. 
A number of factors could stimulate sclerostin production by osteocytes in either 
disorder. It has recently been demonstrated that, Dkk-1, an antagonist of Wnt 
signaling, is also significantly elevated in the serum of patients with Paget’s disease 
of bone [40]. Dkk-1 expression and protein concentration have also been reported 
to be elevated in osteoblastic and stromal cell cultures from Pagetic lesions [41] In 
addition, Dkk-1 has been found to positively regulate sclerostin expression and to 
enhance suppression of the Wnt signaling pathway in inflammatory–induced bone 
loss, so that an increased production of Dkk-1 by Pagetic lesions could also be 
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responsible for increased sclerostin production by osteocytes [42]. Cytokines produced 
by prostate cancer cells, such as BMP-6 [43, 44], which is a known stimulator of 
sclerostin production [45, 46], could also contribute to the increased circulating levels 
of sclerostin observed in prostate cancer metastatic to the skeleton. This increased 
sclerostin production may in turn stimulate RANKL and bone resorption. Sclerostin 
was recently shown to upregulate the expression of RANKL by osteocyte-like cells 
and to promote osteoclastogenesis [15], supporting also the view that osteocytes 
are targets for sclerostin action. This sequence of events can explain the association 
between serum sclerostin levels with those of P1NP and CTX observed in patients 
with prostate cancer metastatic to the skeleton. The same mechanism may not be 
operational in Paget’s disease in which RANKL is already upregulated [47].
In conclusion we demonstrate increased circulating sclerostin levels in two skeletal 
disorders characterized by increased bone turnover, regardless of their underlying 
pathogenetic mechanisms. These increases in serum sclerostin may be due to a 
compensatory response to the increased number of osteoblasts at affected skeletal 
sites and may contribute to increased bone resorption in patients with prostate 
cancer with bone metastases. 
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During the last decade the osteocyte-derived protein sclerostin has emerged as a 
key regulator of bone remodeling. As described in Chapter 1, sclerostin acts as 
an inhibitor of the canonical Wnt pathway in osteoblasts, thereby inhibiting bone 
formation. In patients with sclerosteosis and van Buchem disease impaired sclerostin 
synthesis leads to unrestrained bone formation, and a phenotype of generalized 
hyperostosis with secondary complications due to overgrowth of the skull bones. 
The synthesis of sclerostin is controlled  by systemic and local factors, and aberrant 
sclerostin synthesis is thought to be associated with several bone disorders other 
than sclerosteosis and van Buchem disease. Because the production and function 
of sclerostin is restricted to the skeleton, it presents an attractive target for bone 
building therapies for osteoporosis. The effects of neutralizing antibodies against 
sclerostin on bone mass and strength have been investigated in animal models and 
are currently studied in clinical trials in humans.   
The main objective of this Thesis was the investigation of the regulation of production 
of sclerostin and its effect on bone metabolism in humans. For this, we measured 
circulating sclerostin by an electrochemiluminescence assay developed by Meso 
Scale Discovery Inc. The characteristics, specificity and sensitivity of this assay are 
described in Chapter 2. We determined the specificity of the assay for sclerostin 
by epitope mapping, and we tested the reactivity of sclerostin fragments of different 
lengths. Results showed that the assay is specific for the entire sclerostin molecule 
and sufficiently accurate for use in clinical studies.
In Chapter 3 we describe a study of 19 South African patients with sclerosteosis and 
26 heterozygous carriers of the disease. The purpose of this study was to determine 
the effect of impaired synthesis of sclerostin on the phenotype and bone turnover of 
these individuals. We show that there is a gene-dose effect of the slerosteosis mutation 
on circulating sclerostin, with absent sclerostin in serum of patients and decreased 
serum sclerostin levels in disease carriers, associated with normal phenotype in the 
latter. These differences in circulating sclerostin were accompanied by different levels 
of the bone formation marker serum P1NP between patients, carriers and healthy 
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controls. These results provide in vivo evidence of different degrees of increased bone 
formation caused by the absence or decreased synthesis of sclerostin in humans. They 
also suggest that inhibition of sclerostin can be titrated, since the decreased sclerostin 
levels in disease carriers did not lead to any of the symptoms or complications of the 
disease but had a positive effect on bone mass.
In contrast to sclerosteosis, the SOST gene is unaffected in patients with van Buchem 
disease who lack a regulatory element for the transcription of the gene due to a 52kb 
deletion. In Chapter 4, we describe a study of 15 Dutch  patients with van Buchem 
disease and 28 disease carriers and we show that patients produce small amounts of 
sclerostin. This finding conforms with the previously reported and confirmed in our 
study milder phenotype of the disease compared to that of sclerosteosis. Carriers 
of van Buchem disease had lower sclerostin levels than healthy controls, but the 
overlap with the levels of healthy controls was larger than that found in carriers 
of sclerosteosis. As a result of that, mean levels of serum P1NP although higher in 
carriers compared to controls, were not significantly different. 
 
An important and clinically relevant finding of the studies of sclerosteosis and van 
Buchem disease described in Chapters 3 and 4 was the stabilization of the bone 
complications of these diseases in adulthood. This finding was paralleled by a decline 
in serum P1NP levels with age in both patients with sclerosteosis and van Buchem 
disease, and the stabilization of bone mineral density in patients with van Buchem 
disease. These results strongly suggest that sclerostin is especially critical for bone 
formation during the first two decades of life.
No medical treatment is available for either sclerosteosis or van Buchem disease and 
current management of the complications is surgical, aiming at removal of the excess 
of bone, a technically difficult and sometimes dangerous procedure. Glucocorticoids 
are known inhibitors of bone formation and we hypothesized that administration of 
these agents to patients with complications due to bone overgrowth may arrest their 
progress. In Chapter 5 we present long-term observations of a patient with van 
Buchem disease with life-threatening increased intracranial pressure treated with 
prednisone. Treatment with prednisone resulted in biochemically and histologically 
documented suppression of bone formation and arrest of the progression of bone 
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accumulation. These results suggest that glucocorticoids may offer an alternative 
treatment to the high risk surgical approaches used in the management of patients 
with progressive sclerosing bone diseases. Our findings also suggest that whereas 
sclerostin may not be required for the action of glucocorticoids on bone formation, it 
may well be important for the action of these agents on bone resorption.  
Glucocorticoid use is associated with deleterious effects on bone, particularly bone 
formation, leading to glucocorticoid-induced osteoporosis, a common cause of 
secondary osteoporosis. In mice glucocorticoids increase the expression of the SOST 
gene suggesting a role for sclerostin in the pathogenesis of bone fragility. To assess 
whether glucocorticoids stimulate sclerostin synthesis in humans, in Chapter 6 we 
measured circulating sclerostin in patients with Cushing’s disease and endogenous 
hypercortisolism. Compared to healthy controls, these patients had significantly 
lower plasma sclerostin levels which increased after treatment of the disease. Thus, 
contrary to our hypothesis, sclerostin does not appear to play a role in the effect of 
chronic hypercortisolism on bone formation. Sclerostin is almost exclusively expressed 
by osteocytes, cells that are directly susceptible to the effect of glucocorticoids, 
which promote their apoptosis. We, therefore, investigated the possibility that the 
decreased sclerostin levels in patients with endogenous hypercortisolism may be due 
to a direct effect of glucocorticoids on osteocytes. For this, we measured plasma levels 
of fibroblast growth factor 23 (FGF23), which is also produced by osteocytes. Similar 
to sclerostin, FGF23 levels significantly increased during biochemical remission 
of the disease suggesting that the low sclerostin levels of patients with increased 
endogenous production of cortisol are due to a decrease in the number or function of 
the osteocytes.
In vitro and in vivo studies in animal models have shown that parathyroid hormone 
(PTH) inhibits the expression of the SOST gene and/or sclerostin.  In Chapter 7 
we tested the hypothesis that chronic PTH excess decreases circulating sclerostin in 
humans. For this, we studied 25 patients with elevated serum PTH concentrations 
due to primary hyperparathyroidism (PHPT) and 49 patients cured from PHPT by 
successful parathyroidectomy. We found that patients with PHPT have significantly 
lower serum sclerostin levels compared to patients with normal PTH concentrations 
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following parathyreoidectomy.  The observed negative correlation between PTH and 
sclerostin levels in these individuals strongly suggests that SOST is downregulated 
by PTH in humans.
Patients with Type 2 Diabetes Mellitus (T2DM) have an increased risk of fractures 
and thiazolidinediones (TZDs) increase this risk. Because TZDs stimulate the 
expression of sclerostin in vitro, abnormal sclerostin production may be involved 
in the pathogenesis of increased bone fragility in patients with T2DM treated with 
TZDs. In Chapter 8 we show that men with uncomplicated T2DM have significantly 
higher serum sclerostin levels than healthy controls and that these levels increase 
after treatment with the TZD pioglitazione and are accompanied by increases in 
the levels of the bone resorption marker CTX. These findings suggest that increased 
sclerostin production may be involved in the pathogenesis of skeletal fragility in 
patients with T2DM in general, and may specifically contribute to the detrimental 
effect of TZDs on bone. In contrast, metformin treatment has no effect on serum 
sclerostin levels and it reduces bone turnover having, thus, a more favourable effect 
than pioglitazone on bone metabolism. 
In the previous Chapters we showed that decreased sclerostin synthesis leads to 
an increase in bone formation but may also stimulate bone resorption under certain 
conditions. In Chapter 9 we, therefore, examined the relation between sclerostin 
and bone turnover in diseases characterized by increased bone turnover. For this, we 
measured serum sclerostin levels in patients with Paget’s disease of bone, characterized 
by predominantly increased bone resorption, at different stages of disease activity, 
and in patients with prostate cancer metastatic to the skeleton mainly characterized 
by increased bone formation, at different degrees of skeletal involvement. Compared 
to healthy individuals, mean serum sclerostin levels were significantly higher in both 
disorders and were positively associated with levels of serum P1NP, due possibly to 
a compensatory response to the increased number of osteoblasts at affected skeletal 
sites. Furthermore, sclerostin levels were significantly associated with serum levels of 
CTX in patients with prostate cancer metastatic to the skeleton, but not in patients 
with Paget’s disease of bone and may contribute to the increased bone resorption in 
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patients with prostate cancer metastatic to the skeleton.
Concluding remarks
The described dramatic skeletal phenotypes of sclerosteosis and van Buchem disease 
underscore the essential role of sclerostin in the regulation of bone formation, while 
our findings in carriers of these disorders indicate that milder deficiencies in sclerostin 
synthesis are also associated with increased bone formation but do not to lead to 
complications. The combined results of these studies fully support the rationale of 
the use of sclerostin inhibitors as bone building agents in patients with osteoporosis. 
However, the lack of progression of skeletal complications in both sclerosteosis and 
van Buchem disease in adulthood, and the decline in serum P1NP levels with age 
in patients and carriers, raises questions about the kinetics of bone remodelling 
(transient or continuous) to long-term exposure of elderly individuals to inhibitors 
of sclerostin.
During the investigations described in this Thesis, new data became available 
indicating that sclerostin does not only inhibit bone formation, but can also stimulate 
bone resorption by a RANKL-mediated mechanism in osteocytes. Some of our results 
are fully consistent with these findings and help to explain the complex action of 
sclerostin in humans. Whether measurement of circulating sclerostin can be of use 
in clinical practice is uncertain, due to the substantial overlap of levels between 
healthy subjects and patients and its dependence on numerous modulators. On the 
other hand, it is also clear that sclerostin measurements provide for a very important 
tool for the assessment of the function of osteocytes on bone metabolism in humans. 
The present and previously reported studies illustrate the importance of osteocytes 
in the regulation of bone metabolism and underscore the role of sclerostin as a key 









Gedurende de laatste tien jaar is duidelijk geworden dat het door osteocyten 
geproduceerde eiwit sclerostine een belangrijke regulator is van botombouw. 
Zoals beschreven in hoofdstuk 1 werkt sclerostine als een antagonist van de Wnt 
signaleringsroute in osteoblasten, waarmee het botformatie door deze cellen remt. 
In patiënten met sclerosteose en de ziekte van Van Buchem leidt een gereduceerde 
sclerostine synthese tot ongeremde botformatie, en een fenotype van gegeneraliseerde 
hyperostose met secundaire complicaties door botwoekering in de schedel. De 
synthese van sclerostine wordt gecontroleerd door systemische en lokale factoren, 
en een afwijkende sclerostinesynthese lijkt geassocieerd te zijn met verscheidene 
skeletaandoeningen anders dan sclerosteose en de ziekte van Van Buchem. Omdat de 
productie en functie van sclerostine beperkt is tot het skelet, is het een aantrekkelijk 
aangrijpingspunt voor botopbouwende therapieën voor osteoporose. Het effect van 
neutraliserende antilichamen tegen sclerostine op botmassa en -sterkte is onderzocht 
in verscheidene diermodellen en wordt momenteel in klinische studies in mensen 
bestudeerd.
De doelstelling van dit proefschrift was het bestuderen van de regulatie en productie 
van sclerostine en het effect van dit eiwit op botmetabolisme in mensen. Hiervoor 
hebben wij circulerend sclerostine gemeten met een elektrochemiluminiscentie 
bepaling ontwikkeld door Meso Scale Discovery Inc. De karakteristieken, specificiteit 
en sensitiviteit van deze analyse staan beschreven in hoofdstuk 2. Voor het 
vaststellen van de specificiteit van de bepaling voor sclerostine hebben we de epitopen 
in kaart gebracht, en de reactiviteit van sclerostinefragmenten van verschillende 
lengtes bestudeerd. De desbetreffende resultaten laten zien dat de analyse specifiek is 
voor het gehele sclerostinemolecuul en accuraat genoeg voor het gebruik in klinische 
studies.
In hoofdstuk 3 beschrijven we een studie van 19 Zuid-Afrikaanse patiënten met 
sclerosteose en 26 heterozygote dragers van de ziekte. Deze studie had als doel te 
onderzoeken welk effect een verminderde sclerostineproductie heeft op het fenotype en 
de botombouw van deze individuen. We laten zien dat er een gen-dosis effect is van de 
sclerosteosis mutatie op circulerende sclerostinewaarden, met absentie van sclerostine 
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in het serum van patiënten en verminderde serum sclerostinewaarden in dragers van 
de ziekten, waarbij laatsgenoemden een normaal fenotype hebben. De verschillen in 
sclerostinewaarden gingen gepaard met verschillen in de waarden van de marker voor 
botformatie P1NP tussen patiënten, dragers en gezonde controles. Deze resultaten 
leveren in vivo bewijs voor graduele veranderingen in de mate van botformatie door 
absentie, dan wel verminderde synthese van sclerostine. Dit suggereert ook dat de 
inhibitie van sclerostine kan worden getitreerd, aangezien de verminderde sclerostine 
synthese in dragers niet leidde tot enige symptomen of complicaties van sclerosteose, 
maar wel een positief effect op botmassa had.
In tegenstelling tot sclerosteose is in patiënten met de ziekte van Van Buchem het 
SOST gen onaangetast. Deze patienten missen echter een regulerend element voor 
de transcriptie van het gen door een 52kb deletie op chromosoom 17. In hoofdstuk 
4 beschrijven wij een studie van 15 Nederlandse patiënten met de ziekte van Van 
Buchem en 27 dragers van de ziekte. Wij laten onder andere zien dat patiënten 
geringe hoeveelheden sclerostine produceren. Deze bevinding is in lijn met het eerder 
gerapporteerde, en in onze studie bevestigde, mildere fenotype van deze ziekte ten 
opzichte van dat van sclerosteose. Dragers van de ziekte van Van Buchem hadden 
lagere sclerostinewaarden dan gezonde controles, maar de overlap met de waarden 
van gezonde controles was groter in vergelijking met die gevonden in dragers van 
sclerosteosis. Zodoende waren de gemiddelde waarden van serum P1NP wel hoger in 
dragers dan controles, maar niet significant verschillend.
Een belangrijke en klinisch relevante bevinding van de studies naar sclerosteose en 
de ziekte van Van Buchem, beschreven in hoofdstuk 3 en 4, was de stabilisatie 
van complicaties van de ziekten in volwassenheid. In lijn met deze bevinding was de 
afname van de waarden van P1NP met de leeftijd in patiënten met sclerosteose en 
de ziekte van Van Buchem. De resultaten suggereren in sterke mate dat sclerostine 
met name van groot belang is voor de regulatie van botformatie gedurende de eerste 
twee decennia van het leven.
Er zijn geen medicinale behandelingen voor sclerosteose of de ziekte van Van 
Buchem beschikbaar. De behandeling van complicaties is chirurgisch, gericht op 
het verwijderen van overtollig bot, een technisch ingewikkelde en soms gevaarlijke 
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procedure. Glucocorticosteroïden zijn bekende remmers van botformatie en wij 
beredeneerden dat de toediening van deze medicijnen aan patiënten met complicaties 
ten gevolge van botwoekering de progressie hiervan kon remmen. In hoofdstuk 
5 presenteren we langetermijn observaties van een patiënt met de ziekte van Van 
Buchem met levensbedreigende verhoogde intracraniële druk die werd behandeld 
met prednison. Behandeling met prednison resulteerde in biochemisch en histologisch 
vastgestelde onderdrukking van de botformatie en een arrest van verdere progressie 
van botaccumulatie. Deze resultaten suggereren dat glucocorticosteroïden als een 
alternatieve therapie kunnen dienen voor de risicovolle chirurgische ingrepen waarop 
de behandeling van patiënten met progressieve sclerotiserende botaandoeningen 
momenteel is gestoeld. Onze bevindingen suggereren ook dat alhoewel sclerostine niet 
van belang is voor de invloed van glucorticosteroïden op botformatie, het mogelijk 
wel een rol speelt bij het effect van deze hormonen op botresorptie.
Het gebruik van glucorticosteroïden heeft een negatief effect op het bot, 
waarbij met name botformatie is aangedaan. Glucocorticosteroïd-geïnduceerde 
osteoporose is dan ook een veelvoorkomende oorzaak van secundaire osteoporose. 
Glucocorticoïden verhogen in muizen de expressie van het SOST gen, hetgeen een rol 
van sclerostine suggereert in de pathogenese van botfragiliteit. Om te onderzoeken 
of glucocorticosteroïden ook in mensen sclerostinesynthese stimuleert, hebben we 
circulerend sclerostine gemeten in patiënten met de ziekte van Cushing en endogeen 
hypercortisolisme, zoals beschreven in hoofdstuk 6. Deze patiënten hadden in 
vergelijking met gezonde controles significant lagere sclerostinewaarden, welke stegen 
na behandeling van de ziekte. Dus in tegenstelling tot onze hypothese lijkt sclerostine 
geen rol te spelen in het effect van chronisch hypercorticolisme op botformatie. 
Sclerostine wordt bijna exclusief door osteocyten geproduceerd, cellen waarvan de 
apoptose door glucocorticosteroïden wordt geïnduceerd. Wij hebben zodoende de 
mogelijkheid onderzocht dat de verminderde sclerostinewaarden in patiënten met 
endogeen hypercortisolisme resulteert uit een direct effect van glucocorticoiden op 
osteocyten. Hiertoe hebben we plasmawaarden gemeten van fibroblast groei factor 
23 (FGF23), hetgeen ook uitsluitend door osteocyten wordt geproduceerd. Gelijk 
sclerostine, namen FGF23 waarden significant toe gedurende biochemische remissie 
van de ziekten. Dit suggereert dat de lage sclerostinewaarden van patiënten met 
toegenomen endogene productie van cortisol het resultaat zijn van een verminderd(e) 
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aantal of functie van osteocyten.  
In vitro en in vivo studies in diermodellen hebben laten zien dat parathyroïdhormoon 
(PTH) de expressie van het SOST gen remt. In hoofdstuk 7 testten we de hypothese 
dat chronisch PTH overschot de hoeveelheid circulerend sclerostine in mensen 
vermindert. Hiertoe onderzochten we 25 patiënten met toegenomen serum PTH 
concentraties ten gevolge van primaire hyperparathyreoïdie (PHPT) en 49 patienten 
genezen van PHPT na succesvolle parathyreoïdectomie. We vonden dat patiënten 
met PHPT significant lagere serum sclerostinewaarden hadden in vergelijking met 
patiënten met normale PTH concentraties na parathyroïdectomie. De geobserveerde 
negatieve correlatie tussen PTH en sclerostinewaarden in deze individuen suggereren 
dat ook in mensen SOST expressie wordt geremd door PTH.
Patiënten met type 2 diabetes mellitus (T2DM) hebben een verhoogd risico op 
fracturen en thiazolidinedionen (TZDs) verhogen dit risico nog verder. Omdat TZDs 
de expressie van sclerostine in vitro stimuleren, zou een abnormale sclerostineproductie 
betrokken kunnen zijn in de pathogenese van de toegenomen botfragiliteit in patiënten 
met T2DM die met TZDs worden behandeld. In hoofdstuk 8 laten we zien dat 
mannen met ongecompliceerde T2DM significant hogere sclerostinewaarden hebben 
in vergelijking met gezonde controles en dat deze waarden toenemen na behandeling 
met het TZD pioglitazone. In deze patiënten gingen sclerostinewaarden gepaard met 
een toename van de serummarker van botresorptie CTX. Deze bevindingen suggereren 
dat een toegenomen sclerostineproductie betrokken kan zijn bij de pathogenese van 
skeletfragiliteit in patiënten met T2DM en specifiek zouden kunnen bijdragen aan het 
negatieve effect van TZDs op bot. De behandeling met metformine daarentegen had 
geen effect op serum sclerostinewaarden en het verminderde de mate van botombouw, 
waarmee het een gunstiger effect op botmetabolisme heeft dan pioglitazone. 
In de voorgaande hoofdstukken hebben we laten zien dat verminderde 
sclerostinesynthese tot een toegenomen botformatie leidt, maar dat het ook onder 
sommige condities botresorptie kan stimuleren. In hoofdstuk 9 onderzochten wij 
de relatie tussen sclerostine en botombouw in ziekten die gekenmerkt worden door 
een sterke toegenomen botombouw. Hiertoe hebben wij sclerostinewaarden gemeten 
in patiënten met de ziekte van Paget, gekenmerkt door met name een verhoogde 
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botafbraak, in verschillende fasen van ziekte activiteit, en in patiënten met naar het 
bot gemetastaseerd prostaatcarcinoom, met name gekenmerkt door een toegenomen 
botformatie, met verschillende mate van ossale metastasering. In vergelijking met 
gezonde controles waren gemiddelde sclerostinewaarden significant hoger in beide 
aandoeningen en waren zij positief geassocieerd met de waarden van P1NP, mogelijk 
ten gevolge van een compensatoire respons tegen het toegenomen aantal osteoblasten 
in de betrokken skeletlocaties. Daarnaast waren sclerostinewaarden significant 
geassocieerd met waarden van CTX in patiënten met prostaatkanker, maar niet in 
patiënten met de ziekte van Paget, hetgeen mogelijk bijdraagt aan de toegenomen 
botresorptie in patiënten met ossaal gemetastaseerd prostaatcarcinoom.
Concluderende opmerkingen
De beschreven dramatische skeletfenotypen van sclerosteose en de ziekte van Van 
Buchem illustreren de essentiële rol van sclerostine op de regulatie van botformatie, 
terwijl onze bevindingen in dragers van deze ziekten aanduiden dat mildere deficiënties 
in sclerostinesynthese ook geassocieerd zijn met een toegenomen botformatie, maar niet 
tot complicaties leiden. De gecombineerde resultaten van deze studies ondersteunen 
het idee voor het gebruik van sclerostineremmers als botopbouwende therapie voor 
osteoporose. Echter, het uitblijven van verdere progressie van skeletcomplicaties in 
volwassenheid bij zowel sclerosteose als de ziekte van Van Buchem, en de daling van de 
waarden van P1NP met de leeftijd in patiënten en dragers, roepen vragen op omtrent 
de kinetiek van botombouw (tijdelijk of continue) bij lange termijn toediening van 
sclerostineremmers in oudere individuen.
Gedurende de onderzoeken beschreven in dit proefschrift werden gegevens 
gepubliceerd die aangeven dat sclerostine niet alleen botformatie remt, maar dat 
het ook botresorptie kan stimuleren door een RANKL-gemedieerd mechanisme in 
osteocyten. Sommige van onze resultaten zijn geheel in lijn met deze bevindingen en 
dragen bij aan een beter begrip van de complexe werking van sclerostine in mensen. 
In hoeverre metingen van sclerostinewaarden van nut zijn in de klinische praktijk is 
onzeker, gezien de aanzienlijke overlapping tussen waarden van gezonde controles en 
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patiënten en de afhankelijkheid van verschillende modulatoren. Aan de andere kant is 
het ook duidelijk dat sclerostinebepaling als een belangrijk middel kan dienen voor de 
inschatting van de functie van osteocyten in botmetabolisme in mensen. De huidige 
en eerder gepubliceerde studies illustreren het belang van osteocyten in de regulatie 
van botmetabolisme en onderstrepen de rol van sclerostine als een sleutelfactor voor 
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